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DEFINITIONS 
Crude 1 year 
prevalence of drug use 
Proportion of the paediatric population who had one 
or more prescriptions issued during the study period. 
  
Medicinal product 
authorised for a 
paediatric indication 
Medicine, which is authorised for use in part or all of 
the paediatric population and in respect of which the 
details of the authorised indication are specified in the 
SPC. 
  
Off-label (paediatric) 
use of medicines 
Use of medicines, which have a local marketing 
authorisation (license), but do not have paediatric 
indications included in the marketing authorisation. 
  
Pharmaceutical 
excipients 
Substances other than the active ingredients, which 
have been appropriately evaluated for safety and are 
intentionally included in a drug delivery system 
(IPEC Europe. 2008). 
  
Prescription rate Ambulatory: number of prescriptions per 1000 child-
ren in the age group / per year. 
Hospital: number of prescriptions per 100 admissions. 
  
Prescription 
prevalence rate 
Proportion of treated children of all children in the 
age group. 
  
Unlicensed medicines Use of medicines without local marketing autho-
risation. 
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1. INTRODUCTION 
All people, no matter what their age, should have access to safe and effective 
medicines. Still, while approximately quarter of the global population is under 
15 years of age, children are not always treated in the most safe and effective 
way compared to adults and have even been called  “therapeutic orphans” 
(Shirkey 1999). Many of the currently used medicines have not been clinically 
tested in children, thus have no paediatric labelling and are used off-label (OL). 
It has been shown that paediatric prescribing habits vary greatly between 
countries (Conroy et al. 2000), however, the high rates of OL medicines use 
have been widely described in the Western Europe and North America (Kim-
land et al. 2012), but data are scarce about the Eastern European countries.  
The medicines designed for the adult population and also studied only in 
adults are not always suitable for treating children. Most importantly, children 
and especially neonates are different from adults in terms of their body com-
position and drug metabolising enzymes activity, which affects the pharmaco-
kinetic (PK) profile of the active ingredients (Bartelink et al. 2006), but also 
drug formulation excipients. Thus the way in which children absorb, distribute, 
metabolise and eliminate drugs cannot be predicted from adult data.  
In the absence of clinical trials, data on therapeutic doses for children often 
comes from the clinical experience of prescribers or case reports (Ceci et al. 
2006) resulting in the wide variety of dosing recommendations in different drug 
information sources. The availability of dosing information in different infor-
mation sources e.g. for different paediatric age groups, including neonates has 
been only selectively studied for a few drugs or drug groups.  
Thousands of different pharmaceutical excipients are used in medicines, 
which make up, on average, about 90% of each medicinal product (Haywood & 
Glass 2011). Ideally, an excipient is pharmacologically inactive, non-toxic, and 
does not interact with the active ingredients or other excipients. However, in 
practice few excipients meet these criteria and the safety of pharmaceutical 
excipients is a growing concern for those treating children and especially neo-
nates (Hall et al. 2004). There are currently many unknowns relating to the 
effects of drug formulation excipients in children, including toxicity. Several 
tragedies have occurred in the paediatric population as a result of the excipients, 
which had been tested only in the adult population.  Still to this day only very 
few studies have been published on that topic mainly focusing on the limited 
number of known to be toxic excipients. It is not known how many toxic 
excipients are administered to children within their medicines or neither how 
many of the medicines that are used in children contain toxic excipients.  
Drug utilisation studies involving mainly adult patients have been previously 
conducted in Estonia by R.A. Kiivet. 
Pharmaceutical technology studies including the investigations of pharma-
ceutical excipients have been previously conducted in Tartu University by 
professor P. Veski and professor J. Hein mäki and K. Kogermann. 
   
 
ä
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2. REVIEW OF LITERATURE 
 
2.1. Licensing of medicines 
According to current legislation all marketed medicines are required to have a 
marketing authorisation (MA), which defines their terms of use (European 
Parliament and the Council of the European Union 2001). 
The licensing system of medicines was introduced in the 1960s in the 
aftermath of the thalidomide tragedy to establish certain basic safety procedures 
for MA (Permanand et al. 2006). The Kefauver-Harris amendment to the Food 
Drug and Cosmetic Act in 1962 in the US and European Directive requirements 
for MA in 1965 were the first legislations on licensing of medicines (Wong 
2007). These documents did not include any specific guidance on the licensing 
of paediatric medicines.  
Before a new medicine is available for use in humans, it will pass through 
several development phases such as preclinical and clinical studies. If there is 
enough data on the safety and efficacy, which is relevant to a particular clinical 
indication and a particular age group, a manufacturer can apply for a MA for 
the drug. A licence is a MA issued by the licensing authority. A licensed medi-
cine has been assessed for efficacy, safety, and quality; has been manufactured 
to appropriate quality standards; and when placed on the market is accompanied 
by appropriate product information and labelling. An approved medicine has 
summary of product characteristic (SPC) which outlines the indication(s), 
recommended dose(s), contraindications, and special warnings and precautions 
for use on which the licence is based (European Parliament and the Council of 
the European Union 2001). 
Formerly, new medicines were registered in each EU member state by the 
local regulatory authority. In several cases, the MA of the medicinal product 
was only intended in countries with a large population, such as Germany, 
France, the United Kingdom, Italy, and Spain. Smaller countries could obtain 
these medicines by import from a country that had licensed the medicinal pro-
duct (Breitkreutz 2008). 
Since 1995 the licensing system in Europe consists of a centralised system 
and a decentralised or national (European member states) system. The cent-
ralised system is administered by the European Medicines Agency (EMA) and 
enables the product to have a EU-wide marketing authorisation. The decent-
ralised system is under the control of the member states and the granted MA 
may be recognised by other member states (Irs 2009). 
In Estonia the medicines licensing system is currently administered by the 
State Agency of Medicines (SAM, Ravimiamet), a governmental body under 
the Ministry of Social Affairs. Procedures to obtain MA for the medicinal 
product in Estonia follows the international guidelines and is generally similar 
to that of other EU member states. The requirements of quality, safety and 
efficacy of medicines are based upon the Medicinal Products Act of 2005 
(http://www.sam.ee/en/marketing-authorisation-medicinal-products). 
12 
In the US the Food and Drug Administration (FDA) gives marketing appro-
vals to medicines (http://www.fda.gov), Therapeutic Goods Administration 
(http://www.tga.gov.au) is Australia's regulatory authority for therapeutic goods. 
 
 
2.1.1. Licensing of paediatric medicines 
The early regulatory medicines licensing documents did not include children into 
the drug development processes (Saint-Raymond & Seigneuret 2005). Addi-
tionally to the ambiguous regulatory situation, there were multiple factors limiting 
the number of paediatric clinical trials, such as difficult recruitment to studies due 
to the small number of children suffering from specific condition, more complex 
study design than adult studies (e.g. age-specific drug formulations needed) and 
technical challenges e.g. constraints associated with blood sampling, especially in 
very young children (Kemper et al. 2011, Stötterb 2007). 
The first paediatric medicines regulations were established as late as in the 
middle on 1990s as shown in Table 1.  
 
 
Table 1. Regulatory measures to increase the study and labelling of medicines for 
children (adopted from Hoppu et al. 2008 and Wong 2007) 
 
Regulations Main aim Year of 
approval 
US   
The Final Rule Manufacturers should re-examine existing data to 
determine whether it could be modified to include 
paediatric use information to the SPC  
1994 
Paediatric Rule Manufacturers should conduct studies to provide 
paediatric information on new/marketed drugs 
1998 
 
FDA Modernisation Act 
(FDAMA) 
Paediatric exclusivity provision for manufacturers 
who voluntarily conduct studies in children 
1997 
Best Pharmaceuticals for 
Children Act (BPCA) 
Renewed exclusivity provision under FDAMA, 
additional mechanism for obtaining paediatric  
data for OL drugs 
2002 
Paediatric Research 
Equity Act (PREA) 
Renewed requirement for paediatric studies as a 
law. All applications for new drugs, indication, 
dosage form, dosing regimen or route of administ-
ration must contain a paediatric assessment. 
2003 
EU   
Guidance document on 
the clinical investigation 
of medicinal products in 
children 
Guidance to the safe, efficient and ethical study of 
medicines in children, had no legislative authority 
1997 
EU 
Better Medicines for 
Children 
Provided a legislative framework to facilitate getting 
safety and efficacy information on paediatric drugs 
2002 
EU 
Medicinal products for 
paediatric use 
Established a legislative framework of paediatric 
clinical studies 
2006 
EU 
The Paediatric Regu-
lation No1901/2006 
Established a legislative framework for increasing the 
availability of paediatric medicines, the paediatric 
information and high quality research in children  
2007 
EU 
13 
Currently, The Paediatric Regulation is directly applicable in all EU Member 
States, including Estonia. The main aims of the Regulation are as follows:  
 to make medicines available for children through increasing the develop-
ment of medicines for children by ensuring that the medicines are subject to 
high quality research. At the same time avoiding unnecessary clinical trials 
in children and not delaying the authorisation of medicines for the adult 
population;  
 to implement a new key element of the Regulation, a mandatory Paediatric 
Investigation Plan (PIP) to the process of MA;  
 to create a Paediatric Committee (PDCO), which is responsible for co-
ordinating the EMA's work on medicines for children.  
 
According to the Regulation: 
 Patented medicines:  
For new medicinal products, indications, routes of administration or formu-
lations of already patented products, pharmaceutical companies have to submit 
a PIP to the PDCO. The PIP sets out a programme for the development of a 
medicine in the paediatric population. PDCO considers whether the proposed 
studies will be of significant therapeutic benefit to the paediatric population. 
Also if there is evidence that the medicine is likely to be ineffective or unsafe in 
children, or that the targeted disease occurs only in adult populations or that the 
medicine does not represent a significant therapeutic benefit over existing 
treatments, the PDCO will issue a waiver. PDCO opinion on PIP is transformed 
into EMA decisions. Drugs that comply with the requirement get 6-months 
patent extension.  
 
 Off-patent medicines:  
A new type of MA, the Paediatric Use Marketing Authorisation (PUMA) allows 
10 years of data protection for off-patent products (European Parliament 2004). 
In the US the paediatric medicines licensing system is somewhat more flexible 
than in Europe. The FDA asks pharmaceutical companies a complete Paediatric 
Development Plan (equivalent to PIP in EU) providing any sufficient safety 
data, based on the adult population. When an OL drug is used for a long period, 
US authorities give a paediatric authorisation based on: 1) the number of pae-
diatric patients already treated, 2) available efficacy and safety data collected 
among the paediatric population, 3) the life duration of the OL product use, 4) 
adequate safety data based on adults. Specific and justified paediatric clinical 
studies are demanded only if those points are not met (Knellwolf et al. 2011). 
 Historically, in 2006 around 75% of all centrally authorised medicines were 
relevant for children, but only half of these had indications for using in children 
(http://ec.europa.eu/health/files/paediatrics/2012-09_paediatric_report-annex1-
2_en.pdf). Also the studies published before the approval of the Paediatric Re-
gulation demonstrated a low number of paediatric labelling. The proportion of 
paediatric medicines approved each year under the EMA Centralised Procedure 
from 1995 to 2005 varied between 19% and 48%, with an average level of 33% 
14 
of the total EMA approvals (9.4% in neonates) (Ceci et al. 2006). Of new sub-
stances registered between 1995 and 2001, 58% were of potential use in 
children but only a quarter of those got paediatric authorisation (Strieker et al. 
2002) and the median percentage of drugs authorised for children during these 
years was 35% of the total of commercially available drugs (Ceci et al. 2002). 
The medicines for younger age groups, especially neonates were rarely ap-
proved, the improvements occurred mainly for children over the age of six 
(Ceci et al. 2006, Grieve et al. 2005). Improvements in licensing of medicines 
were greatest in the US subsequent to the Paediatric Exclusivity Provision 
(Grieve et al. 2005). 
 
 
 
2.2. Paediatric drug utilisation studies 
As a part of the pharmacoepidemiology, drug utilisation studies show how medi-
cines are used in real practice and are thus useful for identifying problems in 
paediatric pharmacotherapy. Qualitative drug utilisation studies include the concept 
of appropriateness and use in addition to the prescription data also parameters such 
as indications, daily dose and duration of therapy (Neubert et al. 2008a). 
 
 
2.2.1. Methodology of drug utilisation studies in children 
There are various study designs related to the observational research, all having 
their advantages and limitations. Still, the choice of the most appropriate study 
design to be used depends on the study question.  
 Case report and case series are reports of individual patients or series of pa-
tients experiencing some unexpected event and are therefore of no particular 
use while studying drug utilisation. 
 A cross sectional study measures both exposure to drugs and occurrence of 
disease in an individual or population at a specific time-point (Verhamme & 
Sturkenboom 2011) and has been used for describing drug utilisation in 
children (Nasrin et al. 2002) and OL medicines use (Schirm & Tobi 2002). 
Although cross-sectional studies are quick, easy and inexpensive (Ver-
hamme & Sturkenboom 2011) they offer no real association between the 
exposure and outcome.  
 A cohort study is a study where a group of people with a particular disease 
or taking a particular drug are followed up with regard to the occurrence of 
an outcome of interest. They can study rare exposure and allow the analysis 
of time to event, but are long lasting and expensive (Verhamme & Sturken-
boom 2011). Cohort studies have been used to study paediatric drug utili-
sation patterns over time (Hugtenburg et al. 2004, Thrane & Sørensen 1999). 
Some of the strengths and limitations of different data collection methods are 
described in the Table 2.  
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16 
The common measures that are used in drug utilisation studies are the fol-
lowing: 1) prevalence (number of children who received at least one prescrip-
tion per 100 individuals in the general population) as a measure of exposure and 
2) number of prescriptions and number of medication packages (boxes) as a 
measure of drug consumption (Sequi et al. 2012).  
The measurement of drug exposure/consumption in children is somewhat 
different from the adult studies. As an example, the defined daily doses (DDD) 
is a parameter that is extensively used in adult studies (especially antibiotics use 
studies), but it cannot be used to measure drug consumption in children, since 
the dose recommendations for use in children vary according to age and body 
weight. The DDD is the assumed average maintenance dose per day for a drug 
in its main indication for adults and is commonly expressed with a certain popu-
lation size denominator such as patient days, bed days, admission days, inhabi-
tant days (http://www.whocc.no/filearchive/publications/2010guidelines.pdf.). 
The popularity of the DDD mainly originates from its general applicability and 
its advantage that comparison of the amount of drug use between different 
(international) settings and between different drugs based on grouped dis-
pensing data is possible, without requiring utilisation data on the individual 
patient level. Based on the narrow range of body weights in the neonatal 
population, the investigators have recently developed a set of neonatal DDDs 
for antibiotics (Liem et al. 2010), however no studies using this method were 
currently identified.  
The limitations of using prescription rate as a measure of drug exposure is 
the lack of information on the OTC medicines use.  
According to a recently published literature review, the methodological 
quality of the paediatric drug utilisation studies is rather low. Of the 22 studies, 
all evaluating drug prescriptions published between 1994 and 2008, 10 reported 
the prevalence of drug prescriptions and 16 reported the number of prescrip-
tions and/or medication packages. Only 12 studies reported the prevalence or 
the prescriptions of the most commonly prescribed therapeutic subgroup and 5 
reported the prevalence of the most commonly prescribed drugs. All studies 
defined age groups in different ways, and there was no consistency in the choice 
of groups. The standard deviation (SD) was reported in 5, the range of values in 
6, the 95 % CI in 5, and the median in 4 studies. Statistical analyses were per-
formed in only 12 studies. Only in five of the 18 studies in which the mean was 
used was the SD also reported (Sequi et al. 2012).  
In recent years, national and regional prescription and health maintenance 
organisation databases have been most commonly used in paediatric pharmaco-
epidemiological studies followed by data collected from physicians and ques-
tionnaires administered to parents (Sequi et al. 2012).  
Claims databases are used in the US and health care databases in Europe. 
Health care databases consist of pharmacy, primary care and hospital databases 
(Verhamme & Sturkenboom 2011). Neubert et al. evaluated all of the 16 
population-based European healthcare databases listed on the website of Inter-
national Society of Pharmacoepidemiology (ISPE) and 9 databases known by 
17 
the members of the Task-force in Europe for Drug Development for the Young 
(TEDDY) pharmacoepidemiology expert group which could be used for 
paediatric medicines research. They found that all databases that participated in 
the survey collect information about prescription drugs and the units dispensed 
or prescribed, most of them also record the dosage regimen and are therefore 
particularly useful for studying drug utilisation (Neubert et al. 2008a). 
 
2.2.2. Paediatric drug utilisation studies in practice 
A great number of paediatric drug utilisation studies are conducted and pub-
lished worldwide, however few have been focused on the use of medicines in 
neonates. For example, of the 128 paediatric drug utilisation studies published 
between 1994 and 2008, only 21 were analysing all of the drug groups and of 
these in turn only 11 evaluated drug prescriptions in the entire paediatric 
population, with 3 involving only infants (Clavenna & Bonati 2009). However, 
as a result of the increasing number of OL medicines use studies in neonatal 
units, the neonatal medicines use pattern of recent years has been relatively well 
described.  
Most of the studies have been focusing on a specific drug class, most com-
monly on psychotropic medicines (46% of studies) and antibiotics (30%). Also 
great heterogeneity exists regarding the study types and parameters such as 
study methodology (e.g. prospective vs. retrospective study), population 
(sample size, age group) or setting (outpatient or hospitalised children, general 
practice or specialised unit, certain regional area) making the results of the 
studies hardly comparable (Clavenna & Bonati 2009).  
Furthermore, markedly different data have been collected in trials excluding 
for example standard intravenous replacement solutions, blood products, 
oxygen therapy (Conroy et al. 1999), topical anaesthetic creams (Turner et al. 
2009), drugs given via nebulisation or ear, eye and nose drops (Jain et al. 2008).  
 
Ambulatory practice. The prescription prevalence rate in the paediatric 
ambulatory practice has been ranging from 51% in Denmark and Sweden to 
70% in Greenland, and the prescription rate from 0.8 in Norway to 3.2 in the 
US (Clavenna & Bonati 2009, Olsson et al. 2011). Drug use has been the 
highest among infants decreasing until adolescence (Schirm et al. 2000). 
Most commonly prescribed drug groups were systemic antibiotics, respira-
tory system medicines, analgesics, dermatologicals and ophthalmologicals 
(Mühlbauer et al. 2009, Schirm et al. 2000, Straand et al. 1998, Sturkenboom et 
al. 2008, Thrane & Sørensen 1999) while the most frequent active ingredients 
were amoxicillin, paracetamol, cetirizine and salbutamol (Bazzano et al. 2009, 
Morales-Carpi et al. 2010). 
 
Mixed paediatric population in the hospital, including neonates. The me-
dian number of prescriptions per patient was from three (Pandolfini et al. 2002, 
t Jong et al. 2002) to six (Santos et al. 2008) ranging from 1 to 18. Similarly to 
18 
ambulatory prescribing pattern, the mean number of medications was higher in 
children <1 year old compared to other age groups (Santos et al. 2008). 
The major therapeutic subgroups prescribed were the same as in the ambu-
latory practice – antibacterials for systemic use, respiratory system medicines 
and analgesics/antipyretics (Pandolfini et al. 2002, Santos et al. 2008).  
The list of most frequently used active ingredients was more heterogeneous 
than in ambulatory practice, the most commonly used medicines being vitamin 
D, paracetamol, amoxicillin, beclomethasone, fluconazole, cefotaxime, caf-
feine, prednisolone, benzylpenicillin and nystatin (Hsu & Brazelton. 2009, 
Lindell-Osuagwu et al. 2009, Palčevski et al. 2012, Pandolfini et al. 2002, 
Santos et al. 2008). 
 
Hospitalised neonates received a median number of three to four (Lindell-
Osuagwu et al. 2009, Nguyen et al. 2011, Oguz et al. 2012) to 8.5 medicines 
(Kumar et al. 2008) ranging from 0–132. 
Of all patients 72.5% (Palčevski et al. 2012) up to 99% (Neubert et al. 2010) 
received at least one drug during the hospitalisation.  
According to the ATC classification system again antiinfectives for systemic 
use were prescribed most often followed by the central nervous system and 
respiratory system medicines (Neubert et al. 2010). 
Most commonly used active ingredients were ampicillin, gentamicin, caf-
feine, paracetamol, cefotaxime, heparin, vitamins D and K, salbutamol, furo-
semide, dopamine, midazolam and benzylpenicillin (Clark et al. 2006, Hsu & 
Brazelton 2009, Kumar et al. 2008, Neubert et al. 2010, O'Donnell et al. 2002, 
Oguz et al. 2012, t Jong et al. 2001). 
To conclude, the uniform methodology or large international studies could 
give more comparable data on the paediatric and neonatal medicines use pattern. 
 
 
2.3. Off-label (OL) and unlicensed (UL) use  
of medicines in children 
2.3.1. Definitions 
One of the first definitions of OL/UL use of medicines was published more than 
10 years ago (Turner et al. 1998) and later used in modified version. This 
defines OL use as use of a drug in situations not covered by the product license 
(e.g. administration of a greater dose or more often, administration for 
indications not described in the license, administration to children outside the 
age range for which the product is licensed, the use of alternative routes of 
administration, and use when the product is contraindicated). The UL use is 
defined as modifications to licensed drugs, drugs that are licensed but the 
particular formulation is manufactured under a special license, new drugs 
available under a special manufacturing license (such as caffeine injections for 
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apnoea of prematurity), use of chemicals as drugs, drugs used before a license 
has been granted, and imported drugs. 
 Turner’s definitions were soon abandoned, probably due to the practicalities 
depending on the study methodology. For example as it is complicated to 
evaluate the real intake of medicines prescribed to ambulatory patients, it is also 
difficult to determine whether these drugs are used for licensed indications or in 
a licensed dose (McIntyre et al. 2000, Olsson et al. 2011). 
In earlier drug utilisation studies generally broader definitions for OL were 
used, e.g. a drug use was classified OL if the dose, dosing frequency, or the 
age/weight of the patient was not in agreement with the labelling. In more 
recent studies, OL was mostly defined as a result of the lack of paediatric 
information and the use of a non-approved dose in relation to age (Kimland et 
al. 2012). 
 To overcome the unclarity around the terminology a Delphi survey was 
conducted in 2005 to develop shared definitions for UL/OL drug use in children 
to be used for research and regulatory purposes (Neubert et al. 2008b). The 
following definitions were created: 
 OL use: all paediatric uses of a marketed drug not detailed in the SPC with 
particular reference to therapeutic indication, therapeutic indication for use 
in subsets, appropriate strength (dosage by age), pharmaceutical form and 
route of administration. 
 UL use: all uses of a drug, which has never received a European MA as 
medicinal for human use in either adults or children.  
A widely acceptable definition on the OL/UL use of medicines was still not 
agreed to extend to an international level (i.e. ICH—International Conference 
on Harmonisation) as the EMA opinion was that there is no need to do so from 
the regulatory point of view (Neubert et al. 2008a).  
No uniform definitions across the studies exist for OL/UL medicines use 
making comparisons between studies very difficult if not impossible. As shown 
in Table 3 the OL and UL definitions are also overlapping. For example when 
adult medicine is modified (e.g. tablet is crushed) or when no paediatric dosage 
is available, medicines have been classified both – OL or UL. The list of defi-
nitions used in previous studies reveals many similarities but also crucial diffe-
rences. 
The OL use has been itself divided further to the OL with strong scientific 
support, and OL with limited or no scientific support (Radley et al. 2006). Some 
studies have not distinguished between OL and UL categories (Neubert et al. 
2008b), some have abandoned the OL/UL definitions and assess the age-
appropriateness of medicines (dose capability, suitability of the dosage form 
and inclusion of potentially harmful excipients) finding that paediatric medi-
cines may not be age-appropriate, even if authorised (van Riet‐Nales et al. 
2011). 
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Table 3. Variability of definitions used by investigators while describing UL/OL prescribing 
Category OL category consists Reference 
OL 
D, F, I, A, RA, CI  (Turner et al. 1998) 
D, F, I, A, presentation*  (Carvalho et al. 2003) 
D, I, A, RA, CI, inadvisable co-prescription (Horen et al. 2002) 
D, F, I, A, RA, formulation modification  (Pandolfini et al. 2002) 
 D, F, I, A/weight, RA, CI, dosage form  ('t Jong et al. 2002) 
A, D, RA (Bajcetic et al. 2005) 
A (McKinzie et al. 1997, 
Pasquali et al. 2008, 
Shah et al. 2007) 
Clinically accepted OL indications (Volkers et al. 2007) 
UL 
Formulation modifications, manufactured under special license, 
use of chemicals as drugs, used before a licence has been 
granted, imported drugs licensed for use in another country but 
not in UK 
(Conroy et al. 1999, 
Turner et al. 1998) 
No MA (Tuleu et al. 2010) 
No MA, formulation modification, extemporaneous  (Tuleu C. 2007) 
No MA, not recommended in children  (Serreau et al. 2004) 
Formulation modification  (Gavrilov et al. 2000) 
Formulation modification, CI, no paediatric dosage ('t Jong et al. 2002) 
Not approved for use in children, CI, no paediatric dosage (Carvalho et al. 2003) 
‘Unlicensed’ for age  (Volkers et al. 2007) 
CI, extemporaneous, safety / efficacy in children not established (Santos et al. 2008)  
Extemporaneous, drugs used as ‘‘special’’ formulations, without 
license  
(DellAera et al. 2007) 
MA, marketing authorisation; D, dose; F, frequency; I, indication; A, age; RA, route of admi-
nistration; CI, contraindication 
*OL presentation – prescribers were not aware, that they are using a low viscosity paracetamol 
formulation (1ml = 30 drops) as best known product on the market is 1ml = 16–20 drops. 
Paracetamol was prescribed as though there were 20 drops / ml, leading to under-prescription of 
up to 50% less than intended 
 
 
2.3.2. Extent of OL/UL use of medicines 
As mentioned above the OL/UL prescribing has been extensively studied 
though mainly in Western Europe and US. According to the Neubert et al. a 
total of 66 publications relating to OL/UL drug use in children were identified 
from PubMed database between 1995 and 2005 (Neubert et al. 2008b).  
Pandolfini et al. published a first systematic review of OL/UL use studies in 
2003. They compared paediatric OL/UL drug use in seven European countries 
and across different settings such as neonatal and paediatric hospital wards and 
community setting. The OL/UL drug prescribing rates ranged from 19% of 
patients in community setting to 97% in neonatal wards, and from 11% to 80% 
prescriptions, respectively (Pandolfini & Bonati 2003). 
A review article by the same authors published two years later included 30 
studies from Medline and Embase from 1985–2004. Eleven studies involved 
paediatric hospital wards, seven neonatal hospital wards, and twelve the 
community setting. Most of the studies (21/30) were prospective. Similar 
OL/UL prescription rates were described as in their previous review – from 
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11% to 80%. The proportion of patients receiving at least one OL/UL drug on 
the neonatal wards was much higher than in the paediatric wards and ranged 
from 80% to 97% vs. 36 to 92%. The rates of OL/UL prescriptions in the 
community varied from 55% to 80% (Pandolfini & Bonati 2005). 
Cuzzolin et al. published a review article in 2006. They identified 52 studies 
conducted between 1990 and 2006 assessing the OL/UL use of medicines from 
Medline and Embase database. Again the extent of paediatric UL/OL use was 
found to be higher in neonatal, paediatric intensive care and oncology wards, 
compared with primary care. OL/UL use ranged from 3.3 to 56% of pre-
scriptions in community practice to 36 to 100% in hospital settings (median 
40%) (Cuzzolin et al. 2006). 
The most recent review by Lindell-Osuagwu et al. describes the OL/UL drug 
use in hospitalised children. Data were retrieved through electronic searches of 
Medline and International Pharmaceutical Abstracts. They included 24 studies 
from 12 different countries and found the proportion of children with at least 
one prescription for OL/UL drug ranging from 36 to 100%, including OL pre-
scriptions rate from 18 to 60% and of UL prescriptions rate from 0 to 48%. 
Again UL/OL prescription rate was higher in neonates and small infants as 
compared with all children (98% vs. 88%, respectively) but the differences 
between these two groups were not as pronounced compared to the previous 
reviews (Lindell-Osuagwu et al. 2009).  
With the literature review using Google scholar and Medline database with 
the search terms “off-label”, “unlicensed”, “children”, “neonates” in May 2012 
altogether 40 studies on the hospitalised children (including 7 in the neonatal 
wards) and 17 ambulatory OL/UL medicines use study performed between 
1997 and 2012 were identified (Tables 4 and 5). Only studies in which the rates 
of OL/UL medicines use were reported were included. Again the OL use was 
higher in the hospital setting (median 35% in mixed population including 
neonates, 40% excluding neonates and 49% in pure neonatal studies) compared 
to median of 20% in the ambulatory studies. In contrast, more UL prescriptions 
were issued in the ambulatory setting (median 16%, range 0.3–17%) than in the 
hospital (median 9% in mixed population studies excluding neonates and 
median 12% in both – neonatal studies and mixed population studies including 
neonates). Studies have been mainly conducted in industrialised countries and 
seldom in low- or middle-income countries including Eastern Europe. Of the 20 
countries where hospital-based OL/UL use has been studied, UK predominates 
with 8 studies, followed by The Netherlands (5 studies), Germany and Italy (4 
in both) and Israel (3 studies). In other countries two or less hospital based OL 
studies have been conducted and published.  
Compared to the hospital-based OL use studies the ones in ambulatory 
setting have been conducted even in few countries. As shown in Table 5 of 
eight countries again The Netherlands (4 studies) and UK (3 studies) prevail, 
followed by France, Germany, Sweden and United States (2 studies in each) 
and 1 in Italy and Spain. No studies originate from Eastern Europe or from the 
developing world. 
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2.3.3. OL use according to the therapeutic groups and products 
Drug groups with the highest percentages of ambulatory OL use have found to 
be varying. These include cardiovascular medicines (Olsson et al. 2011, Radley 
et al. 2006), urologicals or sex hormones (mainly oral contraceptives) (Olsson 
et al. 2011, Schirm & Tobi 2002), ophthalmologicals/otologicals (Schirm et al. 
2003), antidepressants (Lee et al. 2011, Volkers et al. 2007) and more 
specifically selective serotonin reuptake inhibitors (SSRIs) (Martin & Conroy. 
1998), hypnotics (e.g. melatonin) and drugs for the musculoskeletal system 
(mainly non-steroidal anti-inflammatory drugs, NSAIDs) (Olsson et al. 2011) or 
respiratory medicines (Morales-Carpi et al. 2010, t Jong et al. 2004). It has been 
found that sixty percent of antidotes and poison treatment agents of children do 
not correspond to the demands of licensing systems (Lifshitz et al. 2001). 
Often used OL products found in published neonatal studies are benzyl-
penicillin (Conroy et al. 1999, Nguyen et al. 2011), amikacin (DellAera et al. 
2007, Nguyen et al. 2011), furosemide, metoclopramide, fentanyl, salbutamol, 
paracetamol (Carvalho et al. 2003), ranitidine, tobramycin (DellAera et al. 
2007), morphine, theophylline and aminophylline (O'Donnell et al. 2002).  
 
 
2.3.4. What problems may OL/UL use of medicines cause? 
The OL use of medicines is legal and sometimes the best practice. An example 
is the recommended use of gentamicin in the combination with ampicillin or 
penicillin in the empirical treatment of neonates at risk of early onset neonatal 
sepsis (Metsvaht et al. 2010) despite the lack of neonatal drug information in 
the Estonian SPC of gentamicin. The use of UL is neither illegal. The Article 
5.11 of Directive 2001/83 allows using an UL medicinal product to meet the 
special needs of an individual patient under the direct personal responsibility of 
prescriber.  
Real negative effects of OL/UL use of medicines have hardly been de-
monstrated in clinical practice or trials. Still, the suspected problems associated 
with OL/UL use of medicines are the following: 
 Lack of suitable paediatric formulation (Tuleu et al. 2010) leading to non-
compliance and potential for treatment failure; 
 Lack of licensed paediatric doses, varying dose ranges in different drug 
information sources (Ceelie et al. 2010) leading to medication errors 
(Conroy 2011). There was for example underdosing of antiretrovirals in the 
UK partly attributable to confusing and inconsistent dosage strategies, failure 
to increase the dose with increases in height and weight or rounding down of 
doses, limitations in formulation (Menson et al. 2006). 
 Lack of long-term safety and efficacy data (Stewart et al. 2007), risk of 
ADRs probably increased while OL medicines were used (Santos et al. 
2008); 
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 Continuity of care after discharge from hospital – availability of OL/UL 
medicine in a public pharmacy once the patient is discharged, no reimburse-
ment (Di Paolo et al. 2006, Wong et al. 2006); 
 Concerns about the quality of UL product and compliance with Good 
Manufacturing Practice (GMP) by the manufacturer;  
 Adequacy of the patient information – the language in package inserts of UL 
drugs is usually not the same as the official language in the country (Di 
Paolo et al. 2006); 
Still, despite the aforementioned problems, there are currently large gaps in our 
understanding of how OL use affects children in real life situations (Smith et al. 
2012). 
 Adverse drug reactions (ADRs) in children are a significant public health 
issue and have been associated with OL prescribing as shown by the prospective 
surveillance study in paediatric inpatients over a 9-month period. The OL 
prescriptions were responsible for 38% of inpatient ADRs and for 42% of the 
ADRs occurring in the community that led to hospitalisation. Urticaria, 
vomiting, rash and tremor were the most common ADRs. Eight ADRs (20%) 
were classified as severe (Impicciatore et al. 2002). 
Horen et al. investigated the potential relationship between OL drug use and 
increased risk of ADRs in paediatric outpatients in France with a prospective 
survey of drug prescribing in office-based paediatricians. They found that the 
relative risk of ADRs with OL drug use was 3.44 (95% CI 1.26, 9.38), 
particularly when it was due to an indication different than that defined in the 
SPC (relative risk 4.42; 95% CI 1.60, 12.25) (Horen et al. 2002).  
Ufer et al. investigated the extent and characteristics of OL prescribing for 
paediatric outpatients among drugs reported to have caused an ADR with a 
retrospective, cross-sectional, observational analysis of spontaneous ADR 
reports in Sweden in the year 2000.   They identified 112 patient-linked reports 
corresponding to 158 ADRs of which 31% were serious. OL drug prescribing 
was 42.4% and it was more frequently associated with serious than non-serious 
ADRs and mostly due to a non-approved age or dose (Ufer et al. 2004). 
Aagaard et al. analysed spontaneous ADR reports for children submitted to 
the Danish national ADR database from 1998 to 2007 with the aim to identify 
ADRs associated with OL prescribing. Of the 4388 of reported ADRs 17% were 
associated with OL use, 60% of them were serious. More than half of OL ADRs 
occurred in adolescents and serious ADRs due to OL prescribing were more 
likely to be reported for hormonal contraceptives, anti-acne preparations and 
allergens (Aagaard & Hansen. 2011). 
 Still, despite the generous amount of publications relating the OL use with 
ADRs and the magnitude of the risk remains unclear (Smith et al. 2012). A 
recent review concluded that although the results of previous studies have 
indicated that there may be some association between OL/UL medicine use and 
ADR risk there is still a lack of clarity (Mason et al. 2012). 
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2.3.5. Data sources for paediatric medicines information  
As there is often a lack of paediatric data in official drug information sources such 
as the SPC, the information necessary for treating children is retrieved from 
paediatric textbooks, national formularies, guidelines etc. Differences in prefe-
rence of drug information source exist between countries, hospitals, and even 
between physicians in the same institution (Kemper et al. 2011). For example, 
British community pharmacists most often use the British National Formulary 
(BNF) or the package insert leaflet for getting the paediatric medicines 
information rather than specialist formularies or guidelines (Stewart et al. 2007). 
Different source documents have also been used to classify medicines into the 
OL category by investigators as shown in Table 6. The availability and reliability 
of paediatric drug dosing guidelines in medicines information sources varies. 
 
 
Table 6. Source documents used by investigators for categorising medicines 
into OL/UL  
 
Source Description Author(s) / reference  
Official drug 
information SPC  
(Hsien et al. 2008, Jong et al. 2002, 
McIntyre et al. 2000, Mühlbauer et al. 
2009, Schirm & Tobi 2002) 
USP DI 2001 (Carvalho et al. 2003, Yoon et al. 2007) 
Swedish catalogue of 
medical products 
(FASS) 
(Kimland et al. 2007) 
Official drug 
information 
combined with the 
expert opinion 
Micromedex database (Carvalho et al. 2003, Yoon et al. 2007) 
BNFC 
(Conroy et al. 1999, Conroy et al. 2003, 
Dick et al. 2003, Jain et al. 2008, 
McCowan et al. 2007, McIntyre et al. 
2000, Porta et al. 2010, Turner et al. 
1998, Turner 1999)    
National 
compendiums 
(product licenses 
summarised) 
The Association of the 
British Pharmaceutical 
Industry’s data sheet 
compendium  
(Conroy et al. 1999, Conroy et al. 2000, 
Conroy et al. 2003, Dick et al. 2003, 
Turner et al. 1998, Turner 1999)  
Repertorium  (Dutch) (Conroy et al. 2000, t Jong et al. 2000) 
Rote Liste (Germany) (Conroy et al. 2000, Hsien et al. 2008, Mühlbauer et al. 2009) 
Israel Drug 
Compendium  
(Gavrilov et al. 2000) 
Vidal (French) (Chalumeau et al. 2000, Serreau et al. 2004) 
Swiss Drug 
Compendium 
(Di Paolo et al. 2006) 
Package insert 
 
 (Conroy et al. 1999, Conroy et al. 2003, 
Di Paolo et al. 2006, Gavrilov et al. 2000, 
McIntyre et al. 2000, Porta et al. 2010, 
Turner et al. 1998, Turner 1999)  
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Source Description Author(s) / reference  
National 
formularies 
Informatore 
Farmaceutico (Italy) 
(Conroy et al. 2000, Porta et al. 2010) 
Greek National 
Formulary 
(Porta et al. 2010) 
Sweden (Conroy et al. 2000, Ufer et al. 2003a)  
Physician’s Desk 
Reference 
Israel (Gavrilov et al. 2000) 
Paediatric drug 
reference book 
Medicines for Children 
(Conroy et al. 2003) 
SPC – Summary of product characteristic  
*Of the 30 studies conducted from 1998 to 2012, in 6 the manufacturer was contacted, 1 
to 8 sources were used for classification drugs OL, 11 used only one source. 
 
Description of different information sources:  
 SPC: a legal document approved as part of the marketing authorization (MA) 
and its information is updated throughout the life cycle of the product as new 
data emerge. The drug manufacturer submits a dossier to the Medicine 
Competent Authority with a proposed SPC. A limitation of the SPC is that 
the data included is from the individual companies proposal to the regulatory 
authorities. The indications that are not claimed by the manufacturer are not 
included into the SPC.  
 Micromedex database (including NeoFax database for neonatal medicines): 
contain both FDA-approved or “labelled” indications as well as unapproved 
or “off-label” indications for drug therapy which are the result of ongoing 
review and recommendations from the worlds’ medical journals by the 
experts (http://www.micromedex.com/ evidence/). Smith et al. examined 
further the drugs without FDA-labelling for paediatric use to identify the 
strength of the evidence behind each indication according to the Micro-
medex website. They found that 41.7% of drugs have indications for which 
the strength of evidence is category C, meaning the evidence for use in 
paediatric patients is based on expert opinion, consensus, case reports, or 
case series, but not clinical trials (Smith et al. 2012). Similarly, Yoon et al. 
found that 27% of all drugs listed in the expert opinion-based Harriet Lane 
Handbook were not approved by the FDA for use in children (Yoon et al. 
2006).  
 BNF and BNFC: use a variety of sources for its information such as SPC, 
expert advisors, systematic literature review (staff editors monitor core 
medical and pharmaceutical journals, databases including the Cochrane 
Library and various web-based resources), consensus guidelines, textbooks 
and reference sources, statutory information, comments from readers and 
industry. Expert advisers provide an opinion in areas of controversy or when 
reliable evidence is lacking and advise on areas where BNF diverges from 
SPC (http://www.bnf.org/bnf/org_450015.htm). 
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An alarming difference in paediatric drug information in different sources is 
described (Hsu & Brazelton 2009) affecting the prescribing of medicines to 
children in different countries and settings. Significantly less prescriptions for 
hospitalised children were classified OL according to the two contemporary 
paediatric reference formularies (Lexi-Comp Pediatric Dosage Handbook and 
the Hospital for Sick Children Handbook and Formulary, and France’s 
Dictionnaire Vidal) compared to the official Canadian Compendium of Pharma-
ceutical Specialties (Doherty et al. 2010). Almost two thirds of the drugs 
prescribed to the Turkish neonates were UL/OL according to national database 
and only 48% according to paediatric dosage handbook (Oguz et al. 2012). 
Ceelie et al. assessed the availability of paediatric information in 4 infor-
mation sources for all the prescribed drugs in 2 ICUs in the Netherlands in 2005 
and 2006. For 34.7% of drugs the daily dosing recommendations differed by 
>100% compared with the formulary for the lowest daily dose to the highest 
daily dose. For 61% of drugs, dosing recommendations differed between 
formularies, whereas for 53.4%, the dosing regimen guidelines differed. The 
dosing guidelines for the three most prescribed drugs (paracetamol, midazolam, 
amoxicillin/clavulanic acid) were provided in all formularies and were largely 
in agreement. At the same time for some of the rarely prescribed drugs such as 
iloprost, no dosing information was given in any of the sources used (Ceelie et 
al. 2010). 
 
 
2.4. Pharmaceutical excipients 
In addition to active ingredients, most drug formulations contain pharmaceutical 
excipients. Excipients aid the manufacturing of the medicinal product and the 
administration to patients.  They are used in medicines as tablet fillers, diluents 
and solvents, emulsifiers, binders, lubricants, glidants, disintegrants, sweeteners, 
preservatives and stabilising, flavouring or colouring agents etc. (Rowe et al. 
2009). 
Excipients are defined as substances other than the active ingredients, which 
have been appropriately evaluated for safety and are intentionally included in a 
drug delivery system (IPEC Europe. 2008). Their use is regulated by several 
documents. According to European guidelines (EMA. 2009), all excipients, 
which are present in the product, should be listed in the SPC, even those present 
in small amounts. In the United States the FDA has published a list entitled 
“Inactive Ingredient Guide” for excipients that have been approved in the 
marketed products providing also the relevant maximum dosage levels by route 
of administration or dosage form (FDA. 2010). WHO has also set an acceptable 
daily intake for several excipients, but despite the recommendation, the amount 
of excipients in the drug formulations has rarely reported in the SPCs. The 
description of excipients in the SPC is either always sufficient to evaluate the 
potential safety of the drug product. For example “orange aroma” could consist 
of 23 different substances, including benzyl alcohol (http://www.theriaque.org/ 
33 
apps/recherche/rch_simple.php#) used as a solvent, which could vaporise during 
the manufacturing but may also stay in the medicinal product as a residual 
solvent. In some other medicinal products, the same generic term “orange 
aroma” includes only two excipients – natural orange essence and malto-
dextrine. It has been found that SPCs of medicinal products approved for sale in 
the United Kingdom and United States report more detail as regards special 
warnings and precautions for use regarding the excipients (Ursino et al. 2011). 
Additionally, in contrast to the manufacturing system of active ingredients, 
excipient quality disasters have happened recently that have heightened 
awareness for the need to better regulate the excipients industry. For example, 
in 2008, 84 children died in Nigeria after consuming teething formula 
containing glycerine contaminated with diethylene glycol (DEG) and in 2006, 
46 people died in Panama after taking cough syrup also contaminated with DEG 
(Monsuur et al. 2010). 
 
 
2.4.1. Paediatric and neonatal issues with  
pharmaceutical excipients 
Excipients generally lack pharmacological action and are therefore historically 
considered to be the inert/inactive ingredients of drug formulation (Fabiano et 
al. 2011). Still, some excipients are clearly not consistently inert in their bio-
logical activity.  
Excipients have the potential to harm patients in two ways. First, by intro-
duction of a chemical hazard (e.g. toxicity, physiological effect) or physical 
(e.g. irritation). Secondly, adversely affecting the drug products availability or 
performance (e.g. changes in the bioavailability or modified release) (Carter 
2011). 
Most of the medicines are administered orally to children, often in a liquid 
formulation. To increase palatability and thereby compliance, colourings, swee-
teners and flavourings are often added to the preparation (Nunn & Williams 
2005). 
Excipients are safe in the majority of adult patients, but can possess danger 
to children for example due to their different PK parameters compared to the 
adults (Tuleu 2007). As an example, benzyl alcohol is oxidised to benzoic acid, 
then conjugated with glycine in the liver, and excreted as hippuric acid in the 
urine. As the pathways involved in the metabolism of benzyl alcohol in 
premature babies are immature, the accumulation of benzyl alcohol can cause 
gasping syndrome (Hall et al. 2004) (Table 7). Risks to children (Fabiano et al. 
2011, Ursino et al. 2011) and particularly to neonates (Whittaker et al. 2009) 
have been emphasised in several publications and also recognised by the drug 
regulatory authorities (Carter 2011). 
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Table 7. Examples of excipients with the safety concerns while used in children / neo-
nates based on the literature data with the examples from infants and adults  (The exhaus-
tive list of excipients and safety problems could be found in publication III, Table 3)  
 Excipient Known safety concerns 
Preservatives Benzyl alcohol 
(BA) 
Gasping syndrome – case report of 24GW neonate 
receiving i.v. clindamycin preserved with BA.  After 
the third dose a profound desaturation and chest 
splinting occurred requiring resuscitation. (Hall et al. 
2004) 
Parabens Contact sensitization – 1,927 adult eczema patients 
were enrolled, patch test for parabens was positive 
for 1.1% (Dastychová et al. 2008) 
Solvents Diethylene glycol 
(DEG) 
Acute renal failure – outbreak due to DEG-conta-
minated cough syrup in Panama (Rentz et al. 2008) 
Propylene glycol 
(PG) 
Coma in a premature infant after receiving a wound 
dressing containing PG. An exceptionally high level 
of PG found in the urine. Cessation of the topical 
treatment resulted in complete recovery. (Peleg et al. 
1998) 
Stabilisers Ethylenediamine Anaphylactoid reaction – 31-year-old man with 
aminophylline (ethylenediamine salt of theophylline) 
allergy and positive intradermal test. (Asakawa et al. 
2000) 
 
 
One of the first reports of excipient toxicity was from 1938 when a liquid pre-
paration of sulphanilamide contaminated with diethylene glycol killed over 70 
people (Geiling & Cannon 1938). In the 1980s intravenous vitamin E prepara-
tion (E-Ferol) was associated with the development of an unusual symptom 
complex of pulmonary deterioration, thrombocytopenia, liver failure, ascites, 
renal failure and fatalities among low birth weight (<1,500 g), premature infants 
in neonatal intensive care units. An inhibitory effect by this vitamin E prepara-
tion was observed on the in-vitro response of human lymphocytes to phyto-
hemagglutinin mixture. Polysorbate 80 used as a carrier in E-Ferol was found to 
be responsible for the suppression (Alade et al. 1986). 
Benzyl alcohol as a preservative in intravascular flush solutions has been as-
sociated with a number of deaths and intraventricular haemorrhage in low-birth-
weight infants (Hiller et al. 1986). 
Haemolysis, central nervous system depression, hyperosmolality, and lactic 
acidosis have been reported after intravenous administration of propylene 
glycol, commonly used in parenteral medication (Arulanantham & Genel 1978). 
There are few data available about the extent to which premature babies and 
neonates are exposed to excipients. Still, it has been shown that neonates are 
exposed to several potentially harmful excipients with the potentially toxic 
doses while receiving routine treatment.  
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As shown by Shehab et al., neonates who received medications by conti-
nuous infusion, median cumulative benzyl alcohol (BA) and propylene glycol 
(PG) exposures were approximately 21 and 180 times the acceptable daily 
intakes of BA and PG, respectively. As the study was retrospective using 
electronic pharmacy record data, possible ADRs to excipients were not recorded 
(Shehab et al. 2009).  
Allegaert et al. assessed prospectively the renal, metabolic and hepatic 
tolerance of PG in 69 (pre)term neonates after i.v. administration of medicines 
containing PG. They found that unintended PG administration (34 mg/kg/24 h) 
for a maximum of 48 h seems to be tolerated in (pre)term neonates and does not 
affect short-term postnatal adaptations (Allegaert et al. 2010). 
Whittaker et al. calculated the quantity of excipients found in the most 
commonly used eight oral liquid medications by retrospectively analysing the 
drug charts of 38 infants less than 30 GW. The amount of excipient each 
preterm baby received was determined on a per kg per week basis. Infants were 
exposed to over 20 excipients including ethanol, PG and high concentrations of 
sorbitol. Many of the infants in the study were exposed to excipient levels that 
were greater than the maximum accepted daily intake in adults (Whittaker et al. 
2009). 
Langley et al. reviewed the excipients levels in paediatric intensive care 
units. They collected data from 5 randomly selected patients and contacted 
manufacturers to ascertain the quantities of excipients present. Patients were 
taking 49 medicines, for only 22% of these the details about excipients were 
received from manufacturers (Langley et al. 2011, not published). 
Cordner et al. aimed to review the suitability of formulations given to the 
hospitalised children and neonates. Excipients within medicines administered 
over 4 weeks in January to February 2010 were identified from SPC or 
contacting the manufacturer and the suitability of each individual excipient was 
assessed following literature review. 80 different medicines were administered 
and 44 excipients were identified that were potentially unsuitable for use in 
children and neonates. Excipients were grouped into four classes: excipients 
that have a potential harmful effect (such as acetone, aspartame, benzoic acid, 
benzyl alcohol, chloroform, citric acid, ethanol, galactose, methylhydroxyben-
zoate, phenol, polysorbate 20 and 80, PG, sodium benzoate, sodium bicarbo-
nate, sodium chloride and sodium dihydrogen phosphate); excipients with 
potential harmful effects only in extremely high concentrations (e.g. diethano-
lamine, disodium edetate, hydrochloric acid, sodium carbonate anhydrous, 
sodium hydroxide, sucrose, sulphuric acid and triethyl citrate); excipients with 
potential to affect the gastrointestinal tract in excess and cause flatulence or act 
as a laxative (e.g. carboxymethylcellulose sodium, croscarmellose sodium, 
hypromellose, magnesium stearate, maltitol liquid and mannitol) and excipients 
with potential to cause an ADR, such as hypersensitivity and anaphylaxis (e.g. 
cetyl alcohol, lactose, polyoxyethylene hydrogenated castor oil, potassium 
sorbate, propylhydroxybenzoate and butylhydroxybenzoate, protamine sulphate, 
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saccharin sodium, sodium lauryl sulphate, sodium metabisulphate, sorbitol and 
tragacanth) (Cordner et al. 2012). 
Studies of excipient exposure have until the present time only been based on 
the concentration in the medicinal product (Allegaert et al. 2010, Whittaker et 
al. 2009), but the concentration of most excipients in the blood of babies has 
never been measured. 
The only earlier classification of excipients according to the potential safety / 
toxicity known to us has been developed by M. Turner (personal communi-
cation): 
1. Excipient is known to cause harm in neonates in some circumstances; 
2. No reports of excipient toxicity are available but the excipient is metabolised 
by pathways known to be immature in neonates;   
3. Excipient is known to cause harm in older age groups but effects on neonates 
not clear;   
4. There are other uncertainties;   
5. Unlikely to cause harm in neonates because they do not cause harm in older 
age groups and metabolism is fully understood.  
  
 
2.5. Summary of the literature 
Throughout the last decade, safer and more evidence-based paediatric 
pharmacotherapy has become a target for clinical practitioners and regulatory 
bodies worldwide. Up to now, many of the medicines are not licensed for use in 
paediatrics (are used OL) or have no marketing authorisation (UL). 
Additionally to the legislative initiatives aiming to increase the paediatric 
medicines licensing status, a substantial amount of paediatric drug utilisation 
studies and OL/UL medicines use studies have been performed and greater 
attention is paid to the quality of these studies.  
The rates of OL/UL use have not been falling in recent years notwith-
standing the combined effort of different specialities. Despite the metho-
dological heterogeneity and various OL/UL definitions used, it has been shown 
that 6 to 100% of children in various age categories, different countries and 
treatment settings have received at least one OL /UL medicine. The extent of 
OL use, however, has been not previously studied in the Eastern-European 
countries or any of the developing or middle-income countries.  
Also the rates of the UL medicines use have wide inter-country ranges – 
from no UL prescriptions to 48%. There is a lack of studies evaluating UL use 
of medicines (mainly defined as the use of medicines with no marketing 
authorisation) in small countries such as Estonia, where the availability of 
medicines is compromised compared to the countries with a larger populations.  
If the medicine is not studied in clinical trials in children, official drug 
information such as SPC is generally lacking. Different information sources are 
then used in practice with the varying dosing guidance and evidence of infor-
mation. It has not been previously shown how the selection of drug information 
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source affects the general rate of OL/UL prescribing and how does the availabi-
lity of drug information differ between official drug information source e.g. 
SPC and expert-consensus based sources such as guidelines and reference 
books.  
Almost every medicinal product contains some pharmaceutical excipient. 
Compared with active ingredients the data on excipients (their content in 
medicines, tolerability and safety in vulnerable populations etc.) is even less 
well known. Furthermore, even if their safety has been evaluated the studies 
have been conducted in adults only or in experimental animals. Despite the 
limited physiological effects in adult population, toxicity resulting from the use 
of pharmaceutical excipients in children has been reported. The highest concern 
is the safety of excipients in neonates, as this is the most vulnerable population 
also presenting the biggest variations in maturation of drug metabolising pro-
cesses. Limited published studies describing the neonatal excipient exposure 
have been focusing on the few well-described toxic excipients, which is only a 
modest fraction of the total excipient list. Still, toxicity or ADR reports have 
been published for many of the substances also used as pharmaceutical exci-
pients. The extent of excipient use, especially of those with known toxicity in 
paediatric population is largely unknown. No validated classification system 
exists until the present time for categorising the pharmaceutical excipients 
according to their potential safety / harmfulness to young children.  
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3. AIMS OF THE RESEARCH 
 
Our general aim was to describe the current situation of paediatric pharmaco-
therapy in terms of the prescription pattern and use of OL/UL medicines in the 
ambulatory and hospital setting and the extent of pharmaceutical excipient 
exposure in hospitalised neonates.  
The specific aims were as follows: 
1. To describe the Estonian paediatric drug utilisation pattern in the outpatient 
setting and in the neonatal wards; 
2. To compare the paediatric ambulatory antibiotic prescription pattern 
between Estonia and Sweden;  
3. To investigate the labelling status of prescribed medicines according to the 
Estonian SPC; 
4. To identify the critical areas in paediatric / neonatal pharmacotherapy where 
drugs are used most commonly and where the information in SPC is most 
often lacking; 
5. To compare the availability of paediatric / neonatal information in Estonian 
SPCs with other widely used drug information sources such as BNFC and 
Thomson Micromedex database; 
6. To develop a classification of excipients depending on their potential 
toxicity present in medicines used in neonatal wards in Estonia;  
7. To describe the presence of toxic and potentially toxic excipients in neonatal 
medicines; 
8. To describe the extent of inpatient neonatal exposure to excipients in general 
and potentially harmful excipients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
39 
4. PATIENTS AND METHODS 
 
The thesis consists of three studies and additional analysis of the data collected 
on the neonatal use of medicines as presented in Table 8. 
 
 
Table 8. Description of studies and analyses of the thesis 
Study 
characteristic 
Timing Population / 
prescriptions 
Primary aim Publication 
Cross‐sectional 
drug utilisation 
study  
1.01.2007 – 
31.12.2007 
467 334 prescriptions 
dispensed to 151 476 
subjects up to 18.99 
y from the EHIF 
database 
To describe the 
accordance of the 
ambulatory paediatric 
prescriptions to the 
Estonian SPCs 
I 
Prospective 
cohort study in 
neonatal wards 
1.02. –
1.08.2008 in 
TUC and 1.02. 
–1.08.2009 in 
TCH 
348 neonates PNA 
<29d 
To investigate the 
labelling status of 
prescribed drugs 
according to the 
Estonian SPC 
 
II 
Excipients use 
study 
Post-hoc 
analysis of 
neonatal study 
data 
348 neonates PNA 
<29d 
To estimate the extent 
of excipient exposure 
in hospitalised 
neonates 
III 
Comparative 
antibiotic use 
study 
1.01.2007 – 
31.12.2007 
159 304 prescriptions 
from EHIF and 681 
954 from SPDR 
database for children 
up to 17.99y  
To compare the 
paediatric outpatient 
antibiotic use in 
Estonia and Sweden  
IV 
EHIF, Estonian Health Insurance Fund; PNA, postnatal age; SPC, summary of product 
characteristic; SPDR, Swedish Prescribed Drug Register TUC, Tartu University Clinics; 
TCH, Tallinn Children’s Hospital; y, year; d, days 
 
 
 
4.1. Ethics 
Prescription database studies did not need the ethics committee approval as no 
personal identifiers were collected.  
Prospective cohort study was approved by the Ethics Review Committee of 
the University of Tartu (No 167/T–9, received 28.01.2008). The study used 
anonymised data collected in routine clinical practice and did not require 
individual consent of the parent.  
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4.2. Design of the studies and data collection 
Drug utilisation studies on dispensed ambulatory prescriptions were based 
on the Estonian Health Insurance Fund (EHIF) prescription database and 
Swedish Prescribed Drug Register (SPDR) databases. The period of pre-
scriptions dispensed that was extracted from both databases was from 1.01.2007 
to 31.12.2007. Estonian data for the comparative antibiotic use study was a 
subset of cross-sectional drug utilisation study data.  
Both databases are nationwide prescription databases, containing electro-
nically submitted data of all prescription medicines dispensed by the pharmacies 
to individuals receiving ambulatory care. The Estonian database contains indi-
vidual patient and physician identification numbers and is diagnosis-linked. The 
Swedish database contains product identification and patient’s age but no infor-
mation with regard to dose or indication.   
 
 
Table 9. Data used for cross-sectional drug utilisation and comparative antibiotic use 
study 
Study  Data-
base  
Age 
group 
studied 
Data extracted 
Cross‐sectional 
drug utilisation 
study  
EHIF Up 
to18.99 y 
EHIF: Age and identification code of patient, 
drug data (package code, WHO ATC code, 
brand name and INN, formulation, content per 
dose unit), number of packages dispensed, 
subsequent diagnoses 
Comparative 
antibiotic use 
study 
EHIF  
SPDR 
Up to 
17.99y  
EHIF: same as in cross-sectional study and 
additionally prescriber speciality 
SPDR: aggregated data on the number of pre-
scriptions for each active substance for each 
age group 
ATC, Anatomical Therapeutic Chemical code; INN, International Non-proprietary 
name; WHO, World Health Organization 
Population data were obtained from the Statistics Estonia (http://pub.stat.ee/px-
web.2001/Database/Rahvastik) and from Statistics Sweden (http://www.scb.se). 
 
 
Neonatal drug utilisation study was a prospective cohort study conducted in 
the neonatal intensive care units (NICU) and intermediate-level neonatal wards 
of Tartu University Hospital’s (TUC) Children Clinics and Tallinn Children’s 
Hospital (TCH). All medicines prescribed to neonates with postnatal age <29 
days who were treated at TUC between 1 February and 1 August 2008 and at 
TCH between 1 February and 1 August 2009 were recorded twice weekly from 
the medicines charts by the 3 investigators, including author of the thesis.  
The following information was collected from the hospital records twice a 
week: demographic data [gestational age (GA), birth weight, gender, date of 
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birth], all diagnoses, admission and discharge dates and all prescriptions (inter-
national non-proprietary or product names (INN), doses and duration of treat-
ment and formulations). If only INN name was collected from the patient 
record, the product names were specified from the pharmacy database. We did 
not record the use of standard intravenous replacement solutions, blood pro-
ducts, oxygen, nutritional and technical products (including contrast agents), 
basic creams and ointments, parenteral nutrition solutions, vaccines and vita-
mins (including colecalciferol).  
 
Excipients use study was a post-hoc analysis based on the data collected during the 
prospective cohort study in neonatal wards described above. All of the 
pharmaceutical excipients in medicines used during the study period were primarily 
determined from the SPCs. If the drug product was not registered in Estonia in 
September 2009 and thus the SPC was lacking, the package inserts were used. The 
names of the excipients and synonyms were double-checked from the Rowe’s 
Handbook of Pharmaceutical Excipients (Rowe et al. 2009) and classified into the 
safety categories based on the literature review. The following literature sources 
were used for classification: Rowe’s Handbook of Pharmaceutical excipients 6th ed., 
European Commission guidelines on the excipients in the label and package leaflet 
of medicinal products for human use (European Commission 2003), EMA 
reflection paper formulations of choice for the paediatric population, 2006 (EMA 
CHMP 2006), article by Fabiano et al. (Fabiano et al. 2011) and book from 
Costello et al. (Costello et al. 2007). A PubMed database search was conducted by 
using the name of each identified excipient AND/OR synonyms AND “human 
toxicity” as search terms; no other limiters or terms were used to narrow or widen 
the search. If there were no results in the PubMed search or other abovementioned 
information sources, Google scholar (http://scholar.google.com; last accessed 24th 
September 2011) search was conducted using the same search terms. In this study, 
all excipients for which according to the abovementioned sources there were some 
safety concerns, including the data from experimental studies, and there was no 
neonatal data demonstrating that these are safe were classified as “potentially 
harmful” (Table 11).  
 
 
4.3. Age categories of study population 
The age categories recommended by the ICH were used in studies for dividing 
children into the subgroups. These age ranges reflect biological changes – the 
changes after birth (preterm neonates born before 37 gestation weeks and term 
neonates); the early growth spurt (infants and toddlers from 28 days to 23 
months); gradual growth from 2–11 years; the pubertal and adolescent growth 
spurt and development towards adult maturity (12–18 years) (Stötterb 2007). 
In the prescription database studies the age group 2–11 years was further 
subdivided in terms of the child’s ability to accept and use different dosage 
forms into pre-school children (2–5 years) and school children (6–11 years). 
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The group of preterm neonates was further subdivided into extremely 
preterm (gestational age (GA) <28 weeks), very preterm (28–31 weeks) and late 
preterm (32–36 weeks).  
 
 
4.4. Assessment of licensing status of the medicines 
The following four SPC sections of the medicinal products were reviewed for 
paediatric information as of February 2009 (ambulatory prescriptions) and as of 
September 2009 for neonatal information (prescribed to hospitalised neonates): 
indication (4.1), administration (4.2), contraindications (4.3) and warnings (4.4).  
 Products with the same active substance but different brand name, dosage 
and formulation were evaluated separately as they have separate SPCs.  
 Drugs were then categorised to labelled, OL in terms of age and UL as pre-
sented in the Table 10.  
 A drug was considered OL if it was prescribed to a child below the lowest 
approved age or outside of the age brackets mentioned in the SPC. We did not 
classify drugs to OL based on the indications, formulations and routes of ad-
ministration. OL use was further divided into two groups – OL because of lack 
of paediatric information and OL because of contraindication (CRI).  
 
 
Table 10. Categories of drugs according to the information in SPC 
Category               Information in SPC 
L L for all children Information about paediatric / neonatal use available in point 
4.1 or / and 4.2*; not CRI for children 
L for specific age 
group 
Information about paediatric / neonatal use available in 4.1 or 
/ and 4.2*; Indicated for children over certain age, for 
children able to swallow oral solid dosage forms, for children 
over certain weight 
L for specific age 
group and diagnosis 
Indicated for children over certain age and with specific 
diagnosis 
OL No data Children / neonates not mentioned in SPC or the following 
sentence used: “no data for use in children”, “for using in 
children exists limited information / experience”, “not 
recommended for children because of the limited information 
/ experience”, “not recommended for children because of the 
drug formulation is not appropriate” 
CRI CRI for children / neonates 
CRI for use in specific 
age group 
CRI under certain age, CRI for children under certain weight 
UL  Product has no MA in Estonia, chemicals that were prepared 
into a formulation within the hospital pharmacy  
*SPC topics: indication (point 4.1), administration (point 4.2). 
CRI, contraindicated; L, labelled; OL, off-label; UL, unlicensed; MA, marketing 
authorisation 
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There were four products (less than 0.3% of all prescriptions) prescribed to out-
patient children for which, for the consistency, the weight‐based recommen-
dations were transformed to the age‐based. Enalapril, azitromycin and doxy-
cyclin tablets were recommended for children over 15, 20, 45 and 50 kg, 
respectively. The weights were transformed to the matching age as follows: if 
the product was licensed for use over 15 kg, it got classified as to be licensed for 
children older than 5 years and over 20 kg, for those older than 12 years. If the 
product was labelled for children who are able to ingest solid dosage formu-
lations or for school‐aged children, it was considered to be licensed for children 
over 6 years old. 
Amongst the ambulatory prescriptions 20 most often prescribed OL medi-
cines were chosen to compare the differences in the availability of paediatric 
information in SPC, British National Formulary for children (BNFC) (BMJ 
Group. 2009); Micromedex database (Thomson Reuters Micromedex 2.0), and 
Harriet Lane Handbook 18th ed. (Custer J.W & Rau R.E. 2009).  
 
 
4.5. Classification of excipients according to  
their potential toxicity to neonates 
The classification system of excipients was developed for the study purpose and   
excipients were divided into four categories as detailed in Table 11 based on the 
literature sources described in section 4.2.  
 
 
Table 11. Classification of excipients to which studied neonates were exposed ac-
cording to the literature review 
Category Safety status Description 
1 Potentially safe No ADRs reported 
2 Potentially harmful and known 
to be harmful 
ADRs reported  
3 No safety data found  No data found in the literature on 
human exposure and toxicity 
4 Description of the excipient in 
SPC or PIL unspecific 
Description does not allow a specific 
literature search 
ADR, adverse drug reaction; PIL, product information leaflet 
 
 
4.6. Analysis of the data 
The prescriptions were categorised based on the World Health Organisation’s Ana-
tomical Therapeutic Chemical (ATC) classification system (http://www.whocc.no/ 
atc_ddd_index/). 
Descriptive statistics was used in all of the studies for prescription data and 
demographics. For ambulatory prescriptions the prescription rate in general and 
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in each age group, in ATC group and specific product level (number of pre-
scriptions per 1000 children aged up to 18.99 years or per number of children in 
the age group) and crude 1 year prevalence of drug use in children (proportion 
of patients of the paediatric population who had one or more prescriptions 
issued) were calculated.  
The paediatric antibiotic use was expressed as number of prescriptions for 
systemic antibiotics (ATC code J01) per 1000 children aged up to 17.99 years in 
the population/year and calculated the 95% confidence intervals (CIs) by using 
R64 software (http://www.r-project.org/).  
For neonatal medicines use study in the interest of completeness the data of 
both hospitals and wards was pooled as both hospitals are in general similar and 
follow the same treatment guidelines. The prescription rates (the number of 
prescriptions per 100 admissions) for each hospital (and CIs), drug group and 
each individual drug were calculated. If two or more courses of the same agent 
were given within the same hospitalisation it was reported only once. 
StatsDirect software (ver. 2.7.8) and Welch’s two sample two-tailed t test were 
used to compare continuous variables and the chi-squared test was used to 
compare categorical values. Cochran-Armitage trend test was used to evaluate 
the trends of prescription rates in different GA groups.  
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5. RESULTS AND DISCUSSION 
 
5.1. Demographics of the study populations 
5.1.1. Ambulatory patients in Estonia and Sweden 
Altogether 151 476 subjects aged up to 18.99 years were identified from the 
Estonian Health Insurance Fund (EHIF) prescription database in 2007 as seen in 
Table 12.  
 
 
Table 12. Number of Estonian children who had been receiving a prescription medicine 
during year 2007 divided into the age groups and total number of children in age groups 
in Estonia. 
Age group 
(years) 
Treated children in Estonia  
(unique subjects) 
Total number of children 
Estonia 
< 2 22 949 29 091 
2–5 37 689 52 233 
6–11 33 034 74 202 
12–18.99 57 798 102 989   
Children total 151 476    277 265 * 
* The total number was 258,515 when children aged up to 17.99 years counted for the 
antibiotics use study 
 
 
The paediatric population of children aged up to 17.99 years in 2007 was 7.5 
times smaller in Estonia (n = 258,515) as compared to Sweden (n = 1, 933,920).  
As the Swedish database contains only aggregated data on the number of 
prescriptions for each active substance for each age group, the number of 
unique children with the prescription was not available to us. 
 
 
5.1.2. Hospitalised neonates 
A total of 490 neonates were admitted to the study centres during the study 
periods as seen in Figure 1. 
About 40% of admitted neonates were preterm, of whom 8% were extremely 
premature babies. The ratio of preterm neonates in TUC was higher than that in 
TCH [46%, 95% CI 40%; 53% vs. 37%, 95%CI 31; 42; p = 0.028], but the 
proportion of extremely preterm neonates was greater in TCH compared with 
TUC (10%, 95% CI 7; 15 vs. 5%, 95% CI 3; 9; p = 0.047).  
The proportions of neonates receiving pharmacotherapy were slightly 
different in the two study centres: 156/203 in TUC (77%, 95% CI 71; 82) and 
192/287 in TCH (67%, 95% CI 61; 72), but the difference was not statistically 
different (Chi-square test value 0.017).  
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The respiratory medicines is a heterogeneous ATC group, which can be di-
vided into drugs for cough or asthma and drugs for allergy. As seen from the 
Table 14, antihistamines for systemic use were by far most commonly used 
respiratory medicines.  
Cetirizine drops and desloratadine syrup prevailed for <12 year old children 
and cetirizine + pseudoephedrine tablets and desloratadine tablets lead the list 
for adolescents.  
Second common group selective beta-2 adrenoreceptor agonists for systemic 
use consisted mainly of salbutamol, which was prescribed extensively for 
children of all ages.  
Leukotriene receptor antagonist montelukast tablets were used often in the 
age group 2–5 years.  
Of the local antibiotics fusafungin spray was prescribed, most often to 2 to 5 
year old children. 
 
 
Table 14. Ambulatory prescription rate of respiratory medicines for Estonian children 
(No of prescriptions per 1000 users) 
ATC subgroup (ATC code) 
Age groups (years)  
<2 2–5 6–11 12–18 Total 
Antihistamines for systemic use (R06A) 291 218 78 70 657 
Selective beta-2 adrenoreceptor agonists 
for systemic use (R03AC) 156 179 52 13 400 
Leukotriene receptor antagonists (R03DC) 54 126 42 5 227 
Glucocorticoids for inhalation (R03BA) 29 61 41 11 142 
Nasal corticosteroids (R01AD) 4 39 54 50 147 
Mucolytics (R05CB) 30 70 18 7 125 
Throat preparations, local AB (fusafungin, 
R02AB03) 11 49 33 29 122 
Others 31 56 48 48 183 
Total 607 797 367 232 2003 
AB, antibiotics 
 
 
Respiratory medicines were on of the most commonly used drug group 
similarly to us also in Sweden, Spain and Germany (Morales-Carpi et al. 2010, 
Mühlbauer et al. 2009, Olsson et al. 2011) and salbutamol (Bianchi et al. 2010, 
Sturkenboom et al. 2008) and cetirizine (Schirm et al. 2000) were amongst most 
commonly used respiratory medicines. 
  
Dermatological products were by far more often used in children younger than 
2 years compared to older children as seen in Table 15. Most commonly used 
drug groups for pre-school children were topical corticosteroids and for 
49 
adolescents anti-acne products. Generally, topical products containing fusidic 
acid and hydrocortisone + chlorhexidine (80 and 78 prescriptions / 1000, 
respectively) were most often prescribed. 
Dermatological medicines were in the third place also in Sweden (Olsson et 
al. 2011) and similarly to Estonia, topical corticosteroids were most frequently 
used among the <2-year-old Danish children (Thrane & Sørensen 1999). 
Fusidic acid (1518 and 6273 users / 1000) and hydrocortisone (1287 and 12310) 
were also the most common individual dermatological drugs used in The 
Netherlands and UK, nevertheless the prescription prevalence was considerably 
higher there than in Estonia.  
Not surprisingly, anti-acne preparations comprised an increasing proportion 
among the oldest children also in Denmark (Thrane & Sørensen 1999). 
 
 
Table 15. Ambulatory prescription rate for dermatological medicines for Estonian 
children (No of prescriptions per 1000 users) 
ATC subgroup 
Age group (years)  
<2 2–5 6–11 12–18 Total 
Topical corticosteroids, combinations (D07B) 252 99 42 34 427 
Topical corticosteroids, plain topical (D07A) 127 65 37 41 270 
Topical anti-acne products (D10) 2 1 5 169 177 
Pimecrolimus (D11AH02)  51 30 5 4 90 
Local antifungal products (D01A) 34 13 12 14 73 
Local antibacterial products (D06A) 39 35 16 12 102 
Local anti-psoriatic products (D05A) 0.1 1 5 11 17.1 
Other    3 3 2 5 13 
Total 507 247 124 288 1166 
 
 
5.2.2. Prescription pattern of antibiotics in  
Estonia compared to Sweden 
5.2.2.1. Quantitative differences 
The total paediatric antibiotic use was almost twice as high – 616 per 1000 
(95%CI 613; 619) in Estonia versus 353 per 1000 (95%CI 352; 354) in Sweden 
(Figure 3).  
 As antibiotic prescribing depends antimicrobial susceptibility as well as on 
local prescription habits the quantitative and qualitative regional variations in 
the antibiotics prescription profile are understandable (Clavenna & Bonati 2011, 
Rossignoli et al. 2007). As of many examples, in Italy the antibiotic prescription 
rate was twice as high compared with Denmark (67 Defined Daily Doses per 
1000 inhabitants per day (DDD/TID) vs. 35 DDD/TID, respectively) (Lusini et 
al. 2009) and the children in British Columbia received substantially more 
50 
antibiotic prescriptions than Danish counterparts (608 versus 385 prescriptions 
per 1000 children, respectively) (Marra et al. 2007).  
However, the quantitative differences seen in our study could not be simply 
explained by dissimilarities in resistance levels of common outpatient micro-
organisms, which have been reported to be low in general in both countries. For 
example, in 2005 to 2009, the proportion of methicillin resistant S. aureus has 
ranged between 2% to 9% in Estonia and 0.5% to 1% in Sweden (EARS-NET).  
Similarly to the general prescription pattern in Estonia, the preschool 
children were also most exposed age group to antibiotics. The probable reasons 
for this phenomenon are discussed in the previous section 5.2.1. The highest 
prescription rate of antibiotics in Estonia was found among 2 to 6 year old 
children whereas in Sweden it was highest among those less than 2 years old 
(Figure 3). Adolescents had the lowest rate of antibacterial prescriptions in both 
countries but the difference in favour of Sweden as in all other age groups was 
observed.  
In concordance with our results, the pre-school children have shown to be 
the most exposed age group to antibiotics also by others (prevalence 72%; 
prescription rate 2.2) compared to the older children (prevalence from 14 to 
57% (mean 34%), prescription rate from 0.2 to 1.3) (Rossignoli et al. 2007). 
Previously, a striking difference in antibiotic prescribing between Italy and 
Denmark has been highlighted for children aged from 0 to 9 years (Vaccheri et 
al. 2002). 
 
 
5.2.2.2. Differences in the selection  
of antibiotics between Estonia and Sweden 
A total of 55 different active substances (22 in Estonia and 50 in Sweden) were 
used. However, 90% of prescriptions in both countries were covered by 8 
agents, as seen in Table 1, paper IV.  
Penicillins were the most widely prescribed antibiotics with the similar 
prescription rate in both countries (Figure 3) but the ratio of penicillins of all 
prescriptions was significantly greater in Sweden than in Estonia (74% vs. 
49%).  
In addition, the qualitative selection of penicillins differed considerably – 
extended spectrum penicillin amoxicillin or its combination with beta-lactamase 
inhibitor (amoxicillin + clavulanic acid) were commonly prescribed in Estonia 
whereas narrow spectrum penicillins (e.g. phenoxymethylpenicillin) covered 
half of the prescriptions in Sweden (Figure 4).  
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Similarly to our results for Estonia, extended-spectrum penicillin amoxicillin 
has also been reported to be the most frequently prescribed antibiotic in the 
Netherlands and Canada and amoxicillin with clavulanic acid combination in 
Italy (Clavenna & Bonati 2011).  
The reasons why Estonian physicians tend to prescribe more often wide 
spectrum agents compared to Swedish colleagues have not been systematically 
studied but the likely reasons could involve the relatively liberal guideline 
recommendations. For example, for acute tonsillitis, the Estonian guidelines 
(http://www.haigekassa.ee/raviasutusele/ravijuhendid/andmebaas/tunnustatud), 
in addition to phenoxymethylpenicillin recommend amoxicillin despite the fact 
that S. pyogenes is uniformly susceptible to penicillin (Hraoui et al. 2011). 
Other reasons could involve the pressure from parents to receive the newest 
agents, a limited option for etiologic diagnosis in outpatient setting, the pro-
motional activities of pharmaceutical industry, the lack of detailed knowledge 
due to poor dissemination of guidelines or simply poor adherence to guidelines 
(Hedin et al. 2006). The latter reason could apparently be supported by the 
significant amount of antibiotic prescriptions for acute bronchitis, a disease not 
requiring antibiotic treatment at all.  
Macrolides accounting for 24% of prescriptions were extensively used in 
Estonia (149 prescriptions per 1000) in all age groups, with the highest rates 
observed among children aged 6 to 17 years whereas in Sweden they were used 
less frequently (29 prescriptions per 1000; 8% of all prescriptions) (Figure 3). 
The extended use of macrolides has been related to increased carriage of 
penicillin non-susceptible S.pneumoniae (Lusini et al. 2009) and considered as a 
major driver for the increase in beta-lactam resistance (EARS-Net 2010). The 
inappropriate prescription of that group of antibiotics was one of the initial 
targets for STRAMA programme in Sweden (Mölstad et al. 2009) and 
macrolide treatment of upper respiratory infections is only recommended if the 
patient is allergic to penicillins (Högberg et al. 2005). 
Also the types of macrolides also differed between countries – clarithro-
mycin predominated in Estonia while the parent drug erythromycin was mainly 
used in Sweden (Table 1, paper IV). The preference of clarithromycin by 
Estonian prescribers could possibly be explained by the easier administration 
scheme – twice as compared to four times daily. Slightly better tolerability in 
terms of gastrointestinal side effects of clarithromycin compared to erythro-
mycin has also been reported (Lee et al. 2008).  
 
 
5.2.3. Prescriptions for hospitalised neonates 
A total of 1981 prescriptions for 115 products and 105 active substances were 
administered to 348 neonates. The prescription rate was 5.7 (Table 16), which is 
higher than the ambulatory prescription rate in Estonia (1.7 / 1000), but similar 
to studies from other countries (range from 3 to 7) (Conroy et al. 1999, 
DellAera et al. 2007, O'Donnell et al. 2002, Oguz et al. 2012). However, the 
extent of neonatal drug exposure has found to be varying between studies 
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depending on one hand on the used methodology and on the other hand on the 
treatment habits and guidelines.  
 The median number of products per child (n = 4; range 1 to 26) in our study 
was broadly similar to that in Italy (n = 5.5; range 1 to 15) (DellAera et al. 
2007) and Finland (n = 4.2; range 0 to 19) (Lindell-Osuagwu et al. 2009) but 
was more than half lower that in a recent study from Germany – 8. The latter 
study did not exclude the vitamins and included also the medications given prior 
to the admission to the neonatology ward (e.g. drugs given in the delivery 
room), which could partly explain differences from our study (Neubert et al. 
2010). 
 The prescription rate in preterm neonates was greater than in term neonates 
as seen in Table 16. All of the extremely preterm neonates received pharmaco-
therapy compared to the 59% of full-term babies. Preterm neonates received 
68% of all prescriptions. There was a negative correlation between prescription 
rate and GA, which has been also reported elsewhere (Kumar et al. 2008, 
Neubert et al. 2010, Warrier et al. 2006). 
 
 
Table 16. General prescription pattern in hospitalised neonates 
  Extremely 
preterm 
neonates 
Very 
preterm 
neonates 
Late 
preterm 
neonates
Term 
neonates 
Total 
No of children 
admitted (male) 
41 (22) 53 (27) 105 (49) 291 (170) 490 
(268) 
No of children who 
received drugs (%) 
41 (100) 48 (91) 87 (83) 172 (59) 348 (71) 
No of prescriptions 596 367 376 642 1981 
Prescription rate 14.5 7.6 4.3 3.7 5.7 
No of products used 66 66 65 85 115 
No of active 
substances used 
62 62 61 81 105 
 Number of prescriptions per treated neonate in GA group 
 
 
5.2.3.1. Prescription pattern according  
to the ATC groups for hospitalised neonates 
The drug utilisation pattern in very preterm infants (<31 weeks GA) was diffe-
rent compared with newborns with a higher GA. Similarly to outpatient medi-
cine use antiinfectives for systemic use were the most commonly prescribed in 
all GA categories. These were followed by cardiovascular agents in extremely 
and very preterm neonates, alimentary medicines in late preterm neonates and 
nervous system drugs in term neonates (Figure 5). The same ATC groups have 
been most often prescribed in other neonatal studies (Clark et al. 2006, Warrier 
et al. 2006). 
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Of the central nervous system drugs, fentanyl (from 8 to 30 prescriptions per 
100 admissions depending on the GA) and midazolam (from 5 to 32 pre-
scriptions per 100 admissions) showed a high number of prescriptions. Para-
cetamol parenteral solution and rectal suppositories (9 and 22 prescriptions per 
100 admissions, respectively) were used often in term neonates, but compared 
to our study, it was prescribed rarely in Germany (Neubert et al. 2010). 
 Neonates received medicines mainly via parenteral route (61/107). The other 
routes like oral administration of manipulated crushed tablets or opened 
capsules (19/107), oral liquids (8/107), topical ointments and creams (6/107), 
ophthalmic (5/107), rectal (4/107) and inhalation (4/107) medicines were rarely 
used. The general problems with manipulated dosage forms are lack of infor-
mation on the bioavailability and stability of the manipulated drug (Nahata & 
Allen Jr 2008). Some studies have shown the equal bioavailability of crushed 
tablets with non-manipulated product, for example for the voriconazole (Ashley 
et al. 2007). At the same time administration of crushed tablet of oral angio-
genesis inhibitor pazopanib increased area under the curve (AUC (0–72)) by 
46% compared with the whole tablet administration, Cmax was increased by 
twofold and Tmax decreased by 2h (Heath et al. 2011). 
 Differences in the rates of medicines use according to the ATC classes 
between study centres were observed. These were mainly caused by few active 
substances. Cardiovascular drugs, consisting mainly of dopamine and epi-
nephrine were prescribed more often in TCH (89/100, 95% CI 78–100 vs. 
62/100, 95% CI 52–74 in TUC), and antibacterials were prescribed more often 
in TUC (150/100, 95% CI 133–168 vs. 107/ 100, 95% CI 94–118 in TCH). 
Intra-country difference in prescription prevalence has been also described 
previously (Bianchi et al. 2010; Rossignoli et al. 2007). Although the reasons of 
such in-country differences were not studied one could speculate that lack of 
evidence-based guidelines in treating several neonatal conditions could be one 
of them. 
 
 
5.3. OL use of medicines 
5.3.1. Ambulatory OL use 
Altogether 31% of ambulatory prescriptions were OL in terms of age. The 
majority of those (29%) did not have any information of paediatric use in the 
SPC and 2% were contraindicated (CRI) for the respective age. It is hard to put 
our findings into the context with others due to the great variability in previous 
studies – ranging from 3.2% of OL use in Germany (Mühlbauer et al. 2009) up 
to 51% in Spain (Morales-Carpi et al. 2010). However, when looking at the 
median rate of OL use (20%) our results are still higher (Table 4). 
The great variability of OL medicines use rates found in different studies is 
at least partly attributable to the various definition, number and quality of 
reference sources used for classifying medicines into the OL category but also 
to the study patients and medicines selection. The lower end of OL use has been 
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Our results highlight that the following products could be included in the 
priority list of medicines needing paediatric trials:   
 Dermatological drugs (D): 
Topical corticosteroids and local antibacterials for <12y (hydrocortisone + 
chlorhexidine and fusidic acid products; pimecrolimus for <6y; beta-
methasone and mometasone products for >6 y); 
Anti-acne products for adolescents (clindamycin, aselainic acid and ada-
palene topical products); 
 Opthalmic drugs (S) for all age groups (chloramphenicol and dexamethasone 
products);  
 Respiratory medicines (R): 
Antihistamine cetirizine oral drops for <2y; 
Anti-asthmatic medicines: montelukast tablets for >2y; 
 Alimentary drugs: metoclopramide supp <6y; lipase+ amylase + protease 
caps <6y; drotaverine tabl <6y; insulin analogues (aspart, lispro) >6y; 
 Genitourinary medicines (G): urinary antispasmodics oxybutynin tablets for 
2–12y and oral contraceptives for adolescents; 
 Antiinfectives: Clarithromycin for 2–18y, azitromycin for 2–12y 
  Nervous system drugs (N): nortriptylline tablets for 6–12y. 
In addition, there are medicines which SPCs should probably just updated 
regarding the paediatric use according to the available literature data such as for 
the use of salbutamol syrup in children <2y and amoxicillin capsules for 
adolescents. 
 
 
5.3.1.2. Ambulatory OL products vs. OL prescriptions and  
topical vs. systemic medicines 
In all age groups, the proportion of OL prescriptions was lower than for OL 
products (Figure 8). This is a consequence of the lower prescription rate of the 
OL products when compared to the drugs with adequate labelling.  
Also compared with topical drugs, a markedly smaller proportion of 
systemic agents (less than 40% in all age categories and 10% of prescriptions 
for the 2–5 years old) were OL for children (Figure 8). The proportion of OL 
topical drugs in our study was the highest for those under 2 years old and for 
adolescents— less than 40% of prescriptions had paediatric label.   
It has been also described by others, that systemic drugs are less likely to be 
prescribed UL/OL than non-systemic (Chalumeau et al. 2000, Olsson et al. 
2011, Schirm et al. 2003, Ufer et al. 2003b). The clinical relevance of this is 
debatable. On one hand, ADRs have been disproportionately more often 
reported on systemic than in topical drugs (Schirm et al. 2004). On the other 
hand, however, several cases of significant systemic absorption of topical and 
ophthalmic drugs leading to severe side effects have been observed (Dahshan & 
Donovan 2006, Hutcheson 2007, Phillips 2008). It is widely known that the 
relative systemic exposure of topically applied drugs in children may exceed 
62 
that of adults (Kearns et al. 2003), thus demonstrating a need to increase the 
available amount of information about the use of topical drugs in children.  
 
 
 
 
Figure 8. Proportion of systemic (a) and topical (b) agents and products (c) / pre-
scriptions (d) being labelled, OL due to the lack of data or contraindication 
 
 
5.3.2. OL medicines use in hospitalised neonates 
OL medicines were an essential part of neonatal care – all preterm and 97% of 
treated term neonates received at least one OL/UL prescription suggesting that 
OL use in Estonia is in the upper end as compared to previous studies (48% – 
100%)(Table 5).   
 Altogether 65% of prescriptions were for OL medicines (Table 19), which is 
higher than found in previous studies with the median rate of 49%, ranging from 
28% (Neubert et al. 2010) to 59% (Barr et al. 2002) (Table 5).   
 While almost three-quarters (67/85, 72%) of drug products used in term 
neonates were OL, the respective rates in extremely preterm, very preterm and 
late preterm neonates were all >90% (respectively, 61/66, 92%; 62/66, 94%; 
62/65, 95%).  
The higher proportion of OL medicines found in our study could not be only 
explained by the methodological differences described previously in the review 
section.  
 The extent of UL/OL use in Estonian neonatal wards was found to be 
markedly higher than the general OL rate in the ambulatory setting. This is not 
surprising and is described by others that more OL prescriptions are seen in the 
neonatal, paediatric intensive care, oncology and haematology wards, compared 
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with primary care (Cuzzolin et al. 2006, Palčevski et al. 2012). This suggests 
that if paediatric studies are conducted they will mostly exclude patients with 
severe illness or at extreme age groups. However, namely in these populations 
the PK/PD of the drug is most unpredictable.  
Among the preterm neonates, the markedly higher rate of OL medicines was 
seen in the group of late preterm neonates (Table 18). This phenomenon is not 
well understood. It may be that late preterm infants born at 34 through 36 GW 
are often the size and weight of term infants and may be managed as though 
they are developmentally mature as term neonates (Engle et al. 2007) affecting 
also the selection of medicines. In contrary to our results, higher prevalence of 
OL prescriptions have been found within the full-term neonates compared to 
pre-term neonates (DellAera et al. 2007).  
 
 
Table 18. Number (%) of labelled (L), off-label (OL) and unlicensed (UL) medicines 
prescribed for hospitalised neonates according to the Estonian SPC 
  
Extremely 
preterm 
neonates 
Very 
preterm 
neonates 
Late 
preterm 
neonates 
Term 
neonates 
Total 
L 62 (10) 33 (9) 16 (4) 151 (24) 200 (10) 
OL  369 (62) 249 (68) 300 (80) 369 (57) 1287 (65) 
UL  165 (28) 85 (23) 60 (16) 122 (19) 432 (22) 
Total 596 367 376 642 1981 
 
 
5.3.2.1. OL ATC groups and products for hospitalised neonates 
The proportions of OL/UL prescriptions differed greatly between ATC groups 
(Figure 9). There were only 5 drugs labelled for preterm neonates – phospho-
lipids (2.5% of prescriptions), midazolam (2.4%), epoetin beta (1.6%), ibu-
profen (1.6%) and amikacin (0.1%).  
All alimentary, genitourinary, musculoskeletal and sensory system drugs 
were used OL, whereas the proportion of OL prescriptions was the lowest 
among the dermatologicals, drugs for blood and blood-forming organs and 
respiratory medicines. Of the antibiotic prescriptions used to treat term 
neonates, 83% were for 7 different OL medicines. The highest proportion of OL 
prescriptions for previously mentioned drug groups has been also shown by 
others (DellAera et al. 2007). 
 Most commonly prescribed OL products in our study were gentamicin for all 
age groups, heparin for very preterm neonates and simeticone for very-, late- 
and term neonates (Paper III, Table 3).  
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Contraindicated respiratory system drugs were rarely used for older children, 
but the prescription rate in infants and toddlers was 24/1000 (containing mainly 
fusafungin spray). For pre-school children, contraindicated clemastine tablets 
(2/1000) were prescribed.  
Of the musculoskeletal system medicines, mainly non-steroidal anti-in-
flammatory drugs (NSAIDs) were contraindicated. As an example, diclofenac 
suppositories were prescribed at a rate of 4/1000 for infants, the drug being 
indicated above the age of 1 year.  
 
Neonates. There were only five contraindicated products used in neonates – 
diclofenac, drotaverine, metoclopramide, heparin sodium ointment and ursodeo-
xycholic acid tablets. They were used in small number of patients and none of 
these were prescribed for extremely preterm neonates, still most of these 
medicines are needed in neonatal pharmacotherapy and recommended by the 
guidelines.  
 
 
5.4. Extent of UL use of medicines 
There were 0.05% of ambulatory prescriptions for six products (etosuximide 
capsules (Petnidan® and Suxilep®), salbutamol prolonged release tablets (Vol-
max®), fludrocortisone tablets (Florinef®), hydrocortisone tablets and 
vigabatrine tablets (Sabril®)) that had no MA in Estonia and were categorised as 
being UL. This is much lower than the median UL rate 16% in other studies 
(Table 4) ranging from 0.3 (McIntyre et al. 2000) to 16.8 (t Jong et al. 2004). 
As mentioned above here the UL definition plays the most important role, as all 
of the studies reporting high ambulatory UL rate have been conducted in The 
Netherlands and have classified medicines as being UL if the medicinal pre-
paration was modified, drug lacked paediatric information or was contra-
indicated  (Table 3). Also, as reported by the authors, the amount of pre-
scriptions that is prepared by the Dutch pharmacies is approximately 5%, 
contributing also to the higher rate of UL medicines (Schirm et al. 2003). 
 The amount of UL drugs in the Estonian neonatal wards was in a contrary 
high (22% of prescriptions, and 25% of products used). This is again in the 
upper end of UL rate found in the literature review (range 6–29%, Table 5). As 
for a comparison, not a single UL medicine was used in the paediatric ward in 
Germany (Hsien et al. 2008). Differences between countries might reflect the 
variations in the national approval status. The higher proportion of UL 
medicines in neonatal wards could express the small market for specific 
medicinal products only used in neonatology leading to the lack of interest for 
drug companies to register these products. As an example, caffeine was used for 
treating apnoea in 29/41 extremely and 20/53 very preterm neonates and was 
UL in Estonia during the study period. Parenteral furosemide and heparin were 
the most commonly used cardiovascular drugs in term and extremely preterm 
neonates, and dobutamine was often used in preterm neonates for treating 
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hypotension associated with postnatal adaption and transitional circulation. All 
of these drugs were UL.  
 
 
5.5. Availability of paediatric medicines information 
Notable differences were found when paediatric information in the Estonian 
SPCs of the frequently used OL medicines was compared with other paediatric 
drug information sources. Discrepancies in paediatric drug information in 
different sources exist due to the following reasons: 
 Principal differences of the source documents e.g. official information in the 
SPC vs. expert-opinion based sources such as BNFC;  
 Regulatory discrepancies e.g. EMA and European indications in the SPC, 
BNFC and UK based indications, FDA indications in the Micromedex 
database.  
 
 
5.5.1. Drug information for ambulatory prescriptions 
Differences existed most often in nervous system medicines and anti-infectives. 
The main discrepancy between the information sources was due to different 
age-related indications/contraindications (Table 20). 
There were several products containing the same active ingredient and 
present in the same pharmaceutical formulation, but produced by different drug 
companies having completely different paediatric information in the SPCs. For 
example, in the SPC of cetirizine oral solution, for the brand name Aceterine® 
(Hexal AG), the SPC states that the product is contraindicated for children aged 
under 2 years; whereas the SPC of Zyrtec® (UCB Pharma Oy) does not state 
such contraindication. The drug formulations, including excipients of these two 
products are exactly the same. According to the BNFC, cetirizine is not in-
dicated for use in children aged less than 6 years except for 2–6 year olds for the 
treatment of seasonal allergic rhinitis. According to the Thomson Micromedex, 
cetirizine is indicated for children aged over 6 months for the treatment of 
perennial allergic rhinitis and also chronic urticaria. The 16th edition of Harriet 
Lane Handbook recommends cetirizine for children aged over 2 years without 
mentioning specific indications or contraindications.  
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Another contradictory area in the SPCs is related to the recommendations for 
liquid and solid oral formulations. Although it is generally accepted but not 
thoroughly studied that children aged above 6 years are able to swallow tablets, 
the upper age for liquid formulation is often not specified or is much greater 
than 6 years. For example, amoxicillin/clavulanic acid (Amoksiklav® [Sandoz 
d.d.], Augmentin® [GlaxoSmithKline]) tablets are most likely suitable for 
children aged above 6 years, but the SPC dosing recommendations for 
adolescents were given only for powder for oral suspension. There was no 
reference to paediatric use in the SPC of Augmentin® tablets, at the same time 
the SPC of Augmentin® suspension granules gives dosing information starting 
from 2 months of age. These results are even more intriguing because 
amoxicillin clavulanate has been extensively studied in paediatric population; 
the MEDLINE database search for the term ‘amoxicillin clavulanate’ identified 
265 randomised controlled studies conducted in the age group of 0–18 years. 
We believe that the SPCs should be updated, as the oral suspension may not be 
the best formulation for subjects who could otherwise swallow tablets. 
However, we accept that the prescription of amoxicillin clavulanate tablets to 
adolescents is OL legally and not medically, provided that the bioequivalence 
between the tablets and the liquid formulation has been demonstrated.  
 
5.5.2. Neonatal medicines information 
Main licensing status variations between drug information sources for the 
medicines used in hospitalised neonates were encountered among term neonates 
(Table 21), while the amount of information for preterm neonates was equally 
scarce in all studied sources as presented in (Figure 10). Neonatal information 
was most frequently available in the BNFC and lacking in the SPCs. For term 
neonates, the information was available for 67%, 38% and 24% of prescriptions 
according to the BNFC, Micromedex and Estonian SPC, respectively. 
Similar to older children great differences regarding the neonatal drug infor-
mation in drug information sources in terms of specific drug products were 
found.  For example, according to the SPC, metoclopramide is contraindicated 
for children less than 2 years of age. According to the BNFC it is not licensed 
for use in neonates as a prokinetic, however the doses are still given. According 
to the Micromedex metoclopramide is only licensed for intestinal intubation, 
but doses for neonates are given for treating gastroesophageal reflux disease 
(GERD). Metoclopramide is widely used as prokinetics in neonates despite the 
descriptions of several side effects and lack of evidence to support the use for 
GERD in infants (Hibbs & Lorch 2006).  
Povidone iodine ointment is licensed according to the SPC, has no directions 
for using in neonates according to BNFC and Micromedex and is contraindicated 
for preterm neonates according to the BNFC. Micromedex warns against using 
povidone iodine, as significant transcutaneous absorption of iodine may occur 
after the topical application in infants and raised plasma iodine levels could 
interfere with metabolic and thyroid function (Hudaoglu et al. 2009). 
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Parenteral heparin, preserved with benzyl alcohol (BA), is used UL in Estonian 
neonatal units as it has no local or central EU MA. Some preparations con-
taining no BA are licensed in children according to the BNFC, and Micro-
medex, but it is stated that solutions preserved with BA should not to be used in 
neonates as BA has been related to the “gasping syndrome” (Thomson Reuters 
Micromedex 2.0). The neonatal safety issues with pharmaceutical excipients are 
further discussed in the following section 5.6. 
 
 
5.6. Extent of excipient use 
In total 93 of 107 medicines (87%) and 1620 of 1961 prescriptions (83%) con-
tained at least one excipient. The total number of different excipients was 123. 
 
 
5.6.1. Classification of excipients 
One third of excipients (42/123) was classified as potentially safe (Category 1, 
described in Table 11).  
Another third (47/123) was classified as potentially harmful (Category 2), in-
cluding eight excipients already known to be harmful in neonates e.g. parabens, 
saccharin sodium, sodium benzoate, benzyl alcohol, benzalkonium chloride, 
propylene glycol, polysorbate 80 and ethanol.  
For the remaining 34 excipients human safety / toxicity data was not found 
in the literature (Category 3) or the chemical entity of excipient was not 
described in the SPC thus allowing not conducting the literature search (15/34; 
Category 4) (Paper III, Table 2). Many of the excipients of the previous cate-
gory were flavouring agents such as banana, strawberry, raspberry flavour etc.  
 
 
5.6.2. Neonatal exposure to excipients 
Almost all treated neonates (339/348; 97%) received medicines with at least one 
potentially harmful excipient (Category 2) and as many as 88% (307/348) 
received at least one of the eight excipients known to be harmful in neonates 
(Paper III, Table 2). 
The proportion of medicines containing potentially harmful excipients in 
preterm neonates was even higher in our study than the general rate – 77%. At 
the same time the percentage of used medicines that contained only potentially 
safe excipients was the same in both populations (22%). 
 
 
5.6.3. Presence of potentially and known to be harmful excipients 
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Table 22. Most commonly prescribed medicines (received by >10 neonates) containing 
known to be harmful or potentially harmful excipients 
Rank Active substance, drug 
formulation 
No of  
Pre-
scrip-
tions 
Potentially harmful or known to be harmful 
excipients 
1 Gentamicin, inj solution 200 Parabens, sodium metabisulphite 
2 Simeticone, oral suspension 108 Sodium benzoate, saccharin sodium, silicium dioxide, sodium cyclamate, sorbic acid 
3 Heparin, inj solution 86 Benzyl alcohol, Parabens 
4 Laurilsulphate  + Sorbitol + Sodium citrate, rectal solution 60 Sorbic acid 
5 Salbutamol, nebulisation solution 54 Benzalkonium chloride, propylene glycol 
6 Dobutamine, inj solution 45 Sodium metabisulphite 
7 Epinephrine, inj solution 36 Sodium metabisulphite 
8 Iron, oral solution 32 Parabens, saccharin sodium 
9 Budesonide, nebulisation solution 31 Polysorbate 80, disodiumedetate 
10 Chloramphenicol, opthalmic solution 29 
Benzalkonium chloride, polysorbate 80, 
borax, boric acid 
11 Caffeine, solution 29 Sodium benzoate 
12 Phenobarbital, tablet 29 Silicium dioxide, gelatin 
13 Paracetamol, suppository 29 Disodium hydrogen phosphate 
14 Piperacillin+ tazobactam, inj solution 25 Disodium edetate 
15 Paracetamol, inj solution 24 Disodium hydrogen phosphate 
16 Hydrocortisone, inj solution 23 Benzyl alcohol, disodium hydrogen phosphate 
17 Epoetin beta, inj solution 22 Disodium hydrogen phosphate, glycine, calcium chloride dihydrate, leucine,  
18 Ibuprofen, inj solution 21 Trometamol 
19 Hyoscine butylbromide, tablet 20 Silicium dioxide 
20 Spironolactone, tablet 18 Silicium dioxide 
21 Zidovudine, oral solution 17 Sodium benzoate, saccharin sodium  
22 Fusidic acid, ophthalmic solution 16 Benzalkonium chloride, disodium edetate 
23 Morphine, inj solution 14 Sodium metabisulphite 
24 Phenobarbital, inj solution 13 Benzyl alcohol, propylene glycol 
25 Heparin sodium, topical gel 12 Parabens, ethanol, trietanolamine,  
26 Insulin, inj solution 11 Cresol 
Inj – injection 
 
 
Simeticone oral suspension was the second most commonly prescribed 
medicine, given to 31% of neonates. The simeticone product contained two 
excipients known to cause harm – saccharin sodium and sodium benzoate, and 
also three other potentially harmful excipients – colloidal anhydrous silica, 
sorbic acid and sodium cyclamate (Table 22). 
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Two products contained 3 known to be toxic excipients – cetirizine oral 
drops (parabens, saccharine sodium and propylene glycol) and miconazole 
ointment (parabens, polysorbate 80, ethanol). The number of different poten-
tially toxic excipients to which neonates are exposed is not studied before, but it 
has been shown that on paediatric wards some products contained up to five 
potentially harmful excipients (Cordner et al. 2012). 
The proportion of medicines containing potentially harmful excipients in our 
study is higher than the recently published in the Netherlands where 52% of oral 
liquid formulations and 7% of all parenteral products for the entire paediatric 
population were containing some toxic excipients (van Riet‐Nales et al. 2011). 
This difference is most likely explained by the methodological variations, re-
gional characteristics in marketed product ranges and by differences in classi-
fying excipients into the toxicity categories. In the Dutch study only “known to 
be toxic” excipients were taken into the analysis while in our study a very con-
servative approach was taken and the excipients were classified into the “poten-
tially harmful” category even if only some data on human toxicity had been 
published (also when used as a substance) as one could not assure that the same 
agent does not cause any harm when used in small quantities as an excipient.  
Approximately two thirds of parenterally used products (29/47) contained 
some potentially harmful excipients. The situation was even worse for other drug 
formulations – all of the prescribed rectal, topical, inhalation, oral solutions and 
oral suspensions contained at least one potentially harmful excipient. The use of 
topical agents in neonates was rare, only 8/33 products contained excipient known 
to be toxic to neonates. Only one of the 19 orally administered solid drug 
formulations and one of the five ocular formulations were free of potentially 
harmful excipients. Not surprisingly, most of medicines free from potentially 
harmful excipients were parenteral single-dose antibacterial or antifungal 
formulations (13/ of all the 35 medicines without harmful excipients).  
A total of 19 medicines were licensed for use in neonates (6 for preterm and 
all for term neonates). Approximately half of them (3/6 in preterm and 8/19 in 
term neonates) contained at least one potentially harmful excipient. For example 
epoetin beta product contains leucine, which is moderately toxic by the sub-
cutaneous route, glycine which is moderately toxic by the intravenous route and 
mildly toxic by ingestion, disodium hydrogen phosphate that can cause gastro-
intestinal disturbances including diarrhea, nausea, and vomiting when used as 
an excipient and calcium chloride dihydrate which is toxic by subcutaneous 
route and can also cause dermatitis (Rowe et al. 2009). It has also described by 
others that the paediatric medicines may not be age-appropriate concerning the 
excipients even if the drugs are authorised for use in children (van Riet‐Nales et 
al. 2011). 
The amount of the excipients in the drug formulation was present in the 
SPCs for only two medications (metoclopramide injection solution and esome-
prazole powder for injection). The detailed characteristics of excipients and 
their potential safety issues are described in Paper III, Table 3.  
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6. GENERAL DISCUSSION 
 
6.1. Studies on the paediatric prescription pattern and  
OL medicines use 
Paediatric medicines use has been abundantly studied in recent decades as the 
creation of healthcare databases has broadened the possibilities for pharmaco-
epidemiological studies. However, due to the high heterogeneity among the 
paediatric drug utilisation studies, the systematic and continuous monitoring of 
the drug use in children by conducting multinational collaborative studies is still 
a burning need to improve the rational use of drugs in children (Clavenna & 
Bonati 2009). With our study we demonstrate that cross-national analyses of 
drug utilisation data can aid in highlighting the possible flaws in pharmaco-
therapy such as in our case the great difference in antibiotics use between 
Estonia and Sweden despite the similar resistance profile of most common 
pathogens. On the basis of our results, the prescribing of antibiotics in Estonian 
children may not always be appropriate and these results should motivate 
initiatives with the aim of improving antibiotics prescribing. 
As one of the subsections of the pharmacoepidemiological studies, the OL 
medicines use has been studied extensively during the last number of years. As 
a result, the current OL status of the many commonly used medicines in 
paediatrics has been meticulously proven for different kinds of treatment 
settings and regions. With our studies we show that the OL medicines use rates 
in an Eastern European country are broadly similar with the results of the 
studies conducted in the Western Europe, thus the further studies focusing on 
the general OL use rates are apparently of no great value. We suggest that the 
differences in OL between various studies (Tables 4 and 5) are not caused by 
the interregional differences but are mainly driven by different methodology 
and most of all by differences in the definitions used.  
 
 
6.2. Evidence-based paediatric drug information –  
from where should it come? 
Licensed medicines represent the gold standard for treatment quality, safety and 
efficacy. In comparison to adults, children are commonly treated with medicines 
that are not studied in the paediatric population and are thus often with 
unknown safety and efficacy profile. As we are also exhaustively showing, 
these medicines generally lack official paediatric drug information and are used 
solely based on the expert opinion.  
 There are strict recent regulations for the drug companies while acquiring 
marketing authorisation for a new medicine, such as need for PIP. As a result, in 
the 2 years after the acceptance of the Paediatric Regulation, 564 PIPs / waivers 
were submitted by the pharmaceutical companies, covering nearly 870 
indications (Rocchi et al. 2010). By the end of 2011 the evaluation of 682 PIPs 
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was completed by the PDCO, of these 476 opinions (70%) resulted in an 
agreement of a PIP and 29 PIPS were completed. The completed PIPS have 
been leading to new paediatric indications for 24 medicines and to a drug 
formulation appropriate for the children for 7 medicines. Thirty-four new 
medicines have been centrally authorised since 26 January 2007 with a 
paediatric indication at the time of initial MA, out of these 7 were authorised for 
a use only in the paediatric population (http://ec.europa.eu/health/files/ 
paediatrics/2012-09_paediatric_report-annex1-2_en.pdf). 
 It was stated more than 10 years ago that when a drug is already extensively 
used there is no commercial incentive for a pharmaceutical company to seek an 
amendment to the product licence (Turner et al. 1998). From our studies the 
examples of such OL “old” medicines are diclofenac, metoclopramide or 
drotaverine and there are around 1000 products authorised for adults but used 
also for treating children on the market in Europe at the present time (Kimland 
et al. 2012). Inadequate paediatric labelling of drugs is often attributed to the 
lack of scientific documentation in children due to the lack of clinical trials. 
However, in some cases, the available evidence outside the drug labelling might 
be sufficient to extend the indications to children without further clinical 
studies. For example, of five proton pump inhibitors (PPI) marketed in EU only 
omeprazole has a paediatric indication, but in US 3 out of 5 are authorised for 
children. Still, despite the lack of paediatric data in SPC, the paediatric PK, 
efficacy and safety data of PPIs in the age ranges that are not covered by SPC is 
available in the literature (Tafuri et al. 2009). Similarly, we conclude that high 
rate of OL medicines use is probably the combination of missing clinical study 
data and nature of the regulatory approval process delaying the reflection of 
study results in the SPC. For example when searching in the PubMed database 
(accessed on 19 August 2012) using the key words “neonate”, “pharma-
cokinetics” and “gentamicin”, we identified 201 publications, several of which 
provide dosing recommendations. However, there is still no mention of 
neonates in the Estonian SPC (http://193.40.10.165/SPC/Hum/SPC_12524.pdf, 
confirmed in the Estonian State Agency of Medicines in March 2011). It would 
appear that regardless of the number of studies, the dosing recommendations 
and safety data are still not readily available to physicians. Furthermore 
different dosing recommendations for gentamicin are given in various guidance 
documents (e.g. BNFC, NeoFax, Textbook for Paediatric Infectious Diseases) 
for neonates, which may also confuse the prescribers. 
It has been suggested that the review of the SPCs of some drugs, together 
with the monitoring of clinical practice and with new clinical research, may be a 
step forward to reduce the OL use in children (Marchetti et al. 2007). A system 
how to increase the availability of official paediatric medicines information for 
the “old” OL medicines that have been used for years is currently established 
through the Paediatric regulation (PUMAs) and EU FP7grants.  In order to 
update the SPC with the relevant paediatric information, the EU Paediatric 
Regulation states that paediatric studies that have not previously been assessed 
by the authorities “shall be submitted by the MA holder for assessment to the 
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competent authority” (Paediatric Regulation, articles 45 and 46). The competent 
authority may then update the SPC and may vary the MA accordingly (Kimland 
et al. 2012). According to the EMA 5-year Report, up to the end of 2011 more 
than 18,000 paediatric studies (also published studies) of about 1000 active 
substances have been submitted to the PDCO by the Marketing Authorisation 
Holders and the assessment of these studies has resulted in 65 SPC changes. 
Also the development of 20 off-patent medicines for paediatric use was funded 
by the EU 7th Framework programme (http://ec.europa.eu/health/files/ 
paediatrics/2012-09_paediatric_report-annex1-2_en.pdf). 
Recently, a national law was adopted in France with the aim of strengthening 
the safety of medicines called “Temporary Recommendations for Use” (TRUs). 
This law provides a regulatory process for temporarily supervising the 
prescribing of medicines for indications for which they are not yet licensed. A 
TRU is issued a single time for a medicine for 3 years, it allows to assess the 
benefits and risks of a marketed drugs for an unlicensed indication, to collect 
scientific information and gives pharmaceutical companies the responsibility for 
controlling the OL prescribing. Companies must monitor prescriptions’ adhe-
rence to MAs and if unconventional prescribing is observed, they must inform 
the National Agency of Medicines (Emmerich et al. 2012). 
In an ideal world similarly to the pharmacotherapy of adults the SPC would 
also be the leading source of drug information for the treatment of children. 
Still, taking into account the limitations of the officially approved SPC, which is 
mainly a manufacturer-lead uni-directional provision of clinical trial based 
information (or often a statement of the lack of this information) and, on the 
other hand, the comprehensive information management of the selected 
medicines formularies such as BNFC, the choice of the drug information source 
by the practitioner and accordingly the drug dosage for children probably 
remains an “educated guess” also in the near future.  
 
 
6.3. Prioritisation of paediatric medicines research 
An important aim of the OL/UL studies is to show in detail which medicines, 
groups of medicines or specialties need to be inserted into the paediatric priority 
lists with the highest need to be studied. As the prescribing habits may vary 
between countries and settings, also the list of priority medicines may differ and 
results of a new OL/UL use study either affirm the list or add new priorities. 
Still, one of the important flaws of the OL/UL medicines use studies is the lack 
of uniform definitions leading to the incomparable study results restricting the 
straightforward transformation of study results to the universal paediatric 
priority list.  
There are two recently published lists of paediatric priority medicines having 
different aims and also content. Global Model List of Essential Medicines for 
Children intended for use for children up to 12 years of age by the WHO 
(http://whqlibdoc.who.int/hq/2011/a95054_eng.pdf) comprises of data from 89 
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unique country priority lists. It represents a list of minimum medicine needs for 
a basic health‐care system, listing the most efficacious, safe and cost‐effective 
medicines for priority conditions. The medicines were selected on the basis of 
global burden of disease and the evidence of efficacy and safety for preventing 
or treating maternal, neonatal, and child mortality and morbidity. The list in-
cludes medicines for treating pneumonia, diarrhoea, malaria, vitamin A 
deficiency, medicines for paediatric palliative care, HIV/TB prophylaxis and 
medicines for neonatal care (Hill et al. 2012).  
According to the EMA revised priority list for studies into off-patent pae-
diatric medicinal products published in January 2012 (http://www.ema.europa.eu/ 
docs/en_GB/document_library/Other/2009/10/WC500004017.pdf), the following 
areas are always considered to be of high priority: development of age-
appropriate drug formulations, data in neonates, in infants with oncological 
conditions and for refractory paediatric epilepsy syndromes. It has also been 
shown by investigators that children from 2 to 6 years receive significantly 
more often than other age groups of medicines that are contraindicated due to 
the inappropriate drug formulation and infants tend to receive the drugs which 
are contraindicated for their age on the basis of toxic effects (Bensouda-
Grimaldi et al. 2007) confirming the recommendations from the priority list.  
The EMA priority list for off patent medicines used in children is a basis for 
the 7th Framework Programme of the European Commission, which the manu-
facturing companies can apply for funding studies for medicines, which are in 
the list.  
The priority list should provide guidance on which medicines are the most 
important to be studied. Still, it is acknowledged that the identification of the 
priorities for the research into the medicinal products for paediatric use is partly 
based on subjective criteria and that the identified priorities may change over time 
(van Riet‐Nales et al. 2011). The country-specific and systematic studies of the 
OL/UL use of medicines are therefore helpful for improving the priority list.  
In our studies we identified that the most commonly prescribed OL products 
come from the frequently prescribed ATC groups – systemic antibacterials, 
dermatological and respiratory system drugs. This highlights also the general 
priorities of including these ATC groups in the priority lists in addition to the 
less commonly used medicines for which the paediatric clinical data is lacking.  
Our results are supported by the Olsson et al. who suggested that topically 
used medicines should be considered in greater need of paediatric clinical 
studies (Olsson et al. 2011) and also by the European survey of the paediatric 
medicines use (http://www.ema.europa.eu/docs/en_GB/document_library/ 
Report/2011/01/WC500101006.pdf) which states that among others, the most 
frequent OL medicines are antiasthmatics and antimicrobials (macrolides, 
betalactams plus betalactamase inhibitors and carbapenems).  
However, we believe that the most commonly used OL medicines should be 
critically evaluated before adding new medicines to the priority lists. For 
example, according to our results, instead of including the commonly used beta-
blocker nebivolol, which is OL for children to the list, the use of the licensed 
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medicine metoprolol from the same drug group could probably be recom-
mended in the clinical practice. Also the contraindicated dexketoprofen should 
not be added to the priority list but rather be substituted in the clinical practice 
with the NSAID labeled for the use in children such as ibuprofen. The use of 
contraindicated prescriptions is certainly inappropriate if the labelled alternative 
exists within the same therapeutic group.  
To conclude, the clinical studies are mostly needed for the most commonly 
used OL medicines and also for those in which no alternatives in paediatric 
pharmacotherapy exist. 
 
 
6.4. What to do with the UL medicines? 
The UL rates in different studies have been found to be even more erratic than 
OL rates. However, again the UL definition could have various meanings. For 
example, the drug formulation needs to be modified before it can be 
administered to child (Gavrilov et al. 2000), medicine is not recommended to be 
given to a child (Serreau et al. 2004) or the drug product has no marketing 
authorisation in the country where the study is conducted, but it is licensed for 
use in an other country (Turner et al. 1998). All of these previously mentioned 
reasons for medicines being UL need different handling and solutions for 
reducing the UL use rates.  
Similarly to most other studies (Table 3) we classified medicinal product UL 
if the product had no MA in Estonia nor centrally in the EU. Chemicals that 
were prepared into a formulation within the hospital pharmacy were also 
categorised UL. Generally the UL medicines lack the official drug information 
(SPC) and are supplemented solely with patient information sheets, which are 
not in local language. The number of such medicines was remarkably high 
(22% of prescriptions, and 25% of products) in the neonatal units highlighting 
the need for regulatory action.  
We show that the UL prescribing is a significantly larger problem in the 
neonatal pharmacotherapy compared to the paediatric ambulatory practice. 
However, very few of the UL medicines were specific for neonates such as 
vitamin K and caffeine. Most of the UL medicines are also used in adults (are 
thus also UL in adults), to mention only a few – atropine, furosemide, heparin, 
fenobarbital or petidine injection solutions. Unfortunately none of these 
products have either a central EU marketing authorisation.  
If there are no alternatives for the substitution of the UL medicines with the 
licensed medicines in clinical practice, one way forward in reducing the UL 
medicines usage rates could be the implementation of regulatory initiatives. 
These initiatives could force the manufactures of such medicines to apply for a 
MA or at least to make available the clinical trial documentation. As a result the 
respective regulatory authorities could then provide an official guidance on the 
use of the specific product in the clinical practice.  
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6.5. Drug formulation excipients and safer neonatal 
pharmacotherapy 
We show that hospitalised neonates often receive medicines with potentially 
harmful drug formulation excipients. However, despite the existing literature 
reports about the possible ADRs of pharmaceutical excipients in children, this 
area has up to now received no appropriate attention, as the excipients were 
relative recently called inactive ingredients of the drug formulation. Therefore, 
the awareness of the potential problems with the excipients, especially in 
neonates has remained low in the medical community. We aimed to increase the 
awareness and have highlighted that in addition to the active ingredients 
medicines also contain a lot of excipients which may cause side effects espe-
cially in neonates (e.g. ethanol, propylene glycol and benzoic acid). 
To date very few medicines have been designed with the needs of the neo-
nates in mind and there are few direct data on the safety of specific excipients in 
infants (Nunn & Williams 2005). Still, due to the immature metabolizing 
systems, excipients that are not harmful to older age groups could be harmful to 
neonates even in very low doses. It is possible that even if the excipient is 
known to be harmful, the daily intake will not exceed the toxic threshold due to 
the small quantities used in drug formulations. The general lack of quantitative 
information of the excipients amount in the SPC limits the possibility of the 
practitioner to make an informed decision. For example, from using a parenteral 
gentamicin product, a premature infant weighting 500g and receiving a daily 
dose of 2mg gets a maximum of 0.1mcg of parabens (methyl- and pro-
pylparahydroxybenzoate, parenteral formulations contain up to 0.75% para-
bens). When comparing this value to the allowed daily intake of 10mg/kg body 
weight in adults it is obvious that the quantities are far below the toxic 
threshold. However, the fact that in neonates organs and thus the PK pathways 
are not fully matured may change the situation drastically (Fabiano et al. 2011).  
Up to now, even the toxicity of known toxic excipients has not been clearly 
proven in clinical practice. Thus it has not been established how extensive is the 
possible clinical harm that may be caused by the formulation excipients. For 
example, Allegaert et al. showed recently that a short duration of unintended 
propylene glycol administration at a median dose of 34 mg/kg over 48 hours 
was well tolerated by (pre)term neonates (Allegaert et al. 2010). However, the 
authors stress that the long-term safety of propylene glycol is still not 
established. We believe that the well-known toxic or potentially harmful 
excipients need careful safety assessment and determination of the PK/PD 
profiles in neonates.  
There is an increasing trend for the companies producing cosmetics to 
remove the unwanted excipients from their products. For example, Johnson and 
Johnson are removing all excipients from their baby care products, including 
parabens. If this would also happen in the pharmaceutical industry, a 
substitution in clinical practice between the generic products free from 
potentially toxic excipients could be possible while treating neonates.  
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One way to reduce the neonatal exposure to the potentially toxic excipients 
could be the therapeutic substitution of medicinal products containing only 
potentially safe excipients. The possibility of substitution will be hopefully 
proven by the European Study of Neonatal Exposure (ESNEE, 
http://www.esnee.eu/index.html) project, which is partly taking place also in 
Estonia. As a part of the project, service evaluation questionnaire was carried 
out to collect the list of medicinal products used in the European neonatal 
intensive care units. The excipient content of the almost 2000 different 
medicinal products reported was collected using the SPCs and PILs. The 
preliminary results show several options for substitution, for example the 
currently used gentamicin product could be substituted by the parabens-free 
product. However, before these results are published, withholding the medicines 
is at the moment often the only means of avoiding exposure to the excipients in 
neonatology. 
 
 
6.6. Limitations of the study 
Some limitations of the studies should be noted, which in our opinion do not 
affect the general reliability of the results.  
In the studies for ambulatory medicines use we were not able to register 
over-the-counter drug use, but only prescription medicines. Thus we are 
showing the usage pattern only for the prescription medicines.  
The main weakness in the antibiotics use study comes from the fact that the 
Swedish data collection is not diagnose-linked so we were not able to assess the 
guideline adherence in Sweden. Nor was it possible to describe the between-
country variability of the dose regimens and of the duration of treatment. In 
order to study the between-country variability in treatment practices including 
the choice of antibiotics for different conditions, a prospective study would be 
required.  
We also only captured ambulatory data collected within 1 year and thus were 
unable to analyse the trends in the prescription medicines and also in the 
systemic antibacterials use. However, the drug prescription pattern is found to 
be relatively stable, and even if changes occur, they are seen between specific 
drugs rather than between drug classes. 
The major limitation to the neonatal medicines use study is that we 
addressed a subsection of the issue of the OL use in neonatology, as only the 
drugs prescribed to the hospitalised neonates were included.  However, we 
believe that these limitations did not obviate the adequacy of our conclusions on 
neonatal drug exposure rates and on OL use in Estonia. We did collect data 
about the doses and duration of the treatment, but were unfortunately not able to 
use this information as the doses expressed per body weight often change daily 
in neonates.  
The most important limitation of the excipients exposure study is the lack of 
the information on the exact amounts of excipients in the medicines, which 
83 
precludes us making any conclusions on the quantitative excipient exposure. 
This limitation was beyond our control because manufacturers do not 
disseminate this information. The other challenges are the use of a novel and 
non-validated classification system and the restriction of the study to one 
country only. We did not collect information about the dosage regimens since 
this would have been un-interpretable in the absence of the quantitative 
information about the excipient content of the prescribed medicines. Another 
issue, possibly characteristic also to other small markets, was the significant use 
(22%) of unlicensed medicines and thus the unavailability of the SPCs. In these 
cases the excipient content was recorded according to the package insert 
leaflets. Although we appreciate that only excipients of intravenous, topical and 
ophthalmic products and known to be toxic excipients have to be declared in the 
package leaflet, we assume that this will not significantly affect our conclu-
sions. Finally the study was conducted in a small country and thus these results 
cannot be generalised to other countries. These limitations do not undermine our 
findings that neonates are frequently exposed to a range of potentially harmful 
and known to be toxic excipients.  
 
 
6.7. Suggestions for future research 
Taking into account the various methodological problems in the OL/UL medi-
cines use studies such as various definitions and study methodologies used, we 
believe that the future studies on the OL/UL use of medicines in children should 
rather be prospective studies with the focus on the real clinical impact of the 
OL/UL medicines use in children. For example, what is the impact of the 
OL/UL use to the efficacy and safety of the paediatric medicines or to which 
extent the OL/UL use of medicines in paediatrics could be avoided. For the OL 
medicines, it should be detected whether there is a real lack of clinical data in 
the literature or there is a need for the SPC update while selecting the medicines 
into the priority list.  
As discussed above numerous clinical studies have already been performed 
with some agents and there is hardly any need to conduct another study. Thus, 
instead of conducting another PK study, a meta-analysis of all existing data 
together with the re-analysis of the already collected data by using population 
kinetics and modelling could be a step forward in providing appropriate dosing 
and safety information to practicing physicians.  
Also, before the discussions into the reformulation of medications with safer 
excipients for neonatal use start, the possible harm from excipients must be 
balanced against the positive effect of the medicine and the hazard (how does 
the excipient harm the child) must be adequately characterised. Therefore, 
further studies should make a clinical link between the excipient exposure and 
outcomes focusing on the excipients disposition (PK), clinical consequences 
associated with the excipient exposure and the level of safe exposure, including 
the long-term safety data in neonates.  
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7. CONCLUSIONS 
 
I The reports of paediatric ambulatory prescription and in-hospital medicines 
use show that a substantial amount of medicines are prescribed to Estonian 
children. This highlights the need for in-depth diagnoses-linked pharmaco-
epidemiological studies in more commonly prescribed pharmacothera-
peutic subgroups for ensuring the rationality of paediatric pharmaco-
therapy. 
II  Significant qualitative and quantitative differences in ambulatory anti-
biotics use between Estonian and Swedish children exist. The higher rate of 
antibiotic consumption in Estonia and the apparent high use of broad-
spectrum antibiotics emphasises the need for national activities similar to 
the Swedish STRAMA programme in order to prevent misuse of anti-
biotics. Thus, auditing activities should focus on rational use of antibiotics 
and compliance to evidence based guidelines.  
III  Compared with Western Europe the rates of OL / UL medicines use in the 
ambulatory and hospital setting in Estonia are similarly high. Larger 
proportion of topical than systemically administered medicines was OL. 
Also children under 2 years received OL medicines more often than older 
age groups. This is showing a priority of including the younger paediatric 
age groups and topical drugs into the priority list of medicines that need to 
be studied in children.  
IV There were very few ambulatory prescriptions for UL medicines. The pre-
scription rate of UL drugs in most vulnerable group hospitalised neonates 
was in a contrary high (22% of prescriptions, and 25% of products used), 
indicating the lack of medicines with local marketing authorisation needed 
for treating hospitalised neonates. Clinical trials in neonatal population and 
regulatory initiatives forcing the manufactures of such medicines for 
applying MA could ease the situation.  
V The majority of prescriptions were classified OL due to the lack of data on 
the paediatric / neonatal use in the SPC. There is a distinctly higher 
availability of information in the paediatric handbooks (e.g. BNFC) and 
databases (e.g. Micromedex) compared to the official documents (SPC). As 
for many OL medicines the literature search reveals substantial amount of 
paediatric studies, our results shall bring the attention of the authorities to 
the need for taking action in updating the SPCs. The reasons for a drug not 
being recommended for paediatric use should be provided to inform the 
practitioners and to avoid ineffective and potentially dangerous use of 
medicines in children.  
VI One third of excipients used in hospitalised neonates were classified as 
potentially harmful but of these only eight have been previously classified 
as known to be harmful in neonates (e.g. parabens, saccharin sodium, 
sodium benzoate, benzyl alcohol, benzalkonium chloride, propylene 
glycol, polysorbate 80 and ethanol). There is a need for validated 
classification system regarding the potential neonatal toxicity of excipients.  
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VII As almost all treated neonates received medicines with at least one 
potentially harmful excipient, there is an urgent need for the careful 
toxicological assessment of excipients as the information in the published 
literature is extremely limited. Information about the possible harm 
resulting from excipients and also the quantitative data regarding the 
excipients amount in specific drug products should be made available to 
pharmacists and neonatologists. This will assist the selection of the most 
appropriate medicines for neonates.  When excipients cannot be avoided, 
professionals should have access to quantitative and qualitative information 
that allows them to assess risk, substitute products while toxic-excipient 
free products are available and monitor vulnerable patients appropriately. 
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9. SUMMARY IN ESTONIAN 
 
Ravimikasutuse epidemioloogilised ja  
kliinilised aspektid Eesti lastel 
Lapsed moodustavad suure osa kõigist ravimite tarvitajatest, kuid võrreldes 
täiskasvanutega on nende ravimine sageli keerulisem. Kuna lastel on ravimi-
uuringuid tehtud oluliselt vähem kui täiskasvanutel, ravitakse lapsi sageli vaid 
täiskasvanutel uuritud ravimitega. Sellisest olukorrast tingituna on kasutusel 
kaks mõistet: 
 näidustuseta ravimid (ingl. k. off-label, OL) – ravimit kasutatakse erinevalt 
ravimiomaduste kokkuvõttes märgitust (näiteks erineval näidustusel, vanuse-
rühmal, annuses ja/või manustamisviisil) või on ravim lastele vastu-
näidustatud; 
 litsentseerimata (ingl. k.  unlicenced, UL) ravimid pole Euroopa Liidus kasu-
tamiseks registreeritud ei täiskasvanutele ega lastele.  
OL ravimite kasutamine on Lääne-Euroopas ja Põhja-Ameerikas levinud (Kim-
land et al. 2012), kuid vastavad andmed Ida-Euroopa kohta seni puudusid.  
Täiskasvanutele mõeldud ja vaid täiskasvanutel uuritud ravimid või ravimite 
annused ei sobi alati laste ravimiseks. Lapsed ja eriti veel vastsündinud erinevad 
oluliselt täiskasvanutest organismi koostise (rasvade ja veesisaldus) ning 
ravimeid metaboliseerivate ensüümide aktiivsuse poolest, mis mõjutab nii 
aktiivsete toimeainete kui ka ravimites olevate abiainete farmakokineetilist 
profiili (Bartelink et al. 2006). Seetõttu ei ole enamasti ka võimalik täiskas-
vanutel tehtud uuringutest tuletada, kuidas ravim laste organismis imendub, 
jaotub, metaboliseerub või eritub.  
Kliiniliste uuringute puudumisel pärinevad andmed ravimi annuste kohta 
lastel sageli arstide kliinilisest kogemusest või üksikutest ravijuhtudest (Ceci et 
al. 2006). Seetõttu on ravimite annustamise soovitused erinevates ravimiinfo 
allikates väga erinevad. Lastele ravimite annustamise informatsiooni erinevusi 
pole seni süstemaatiliselt uuritud.  
Ravimvormide koostises kasutatakse tuhandeid erinevaid abiaineid, mis 
moodustavad keskmiselt 90% ravimvormi massist (Haywood & Glass 2011). 
Ideaalis peaks abiaine olema farmakoloogiliselt inaktiivne, mitte-toksiline ja 
mitte omama koostoimeid toimeainete või teiste abiainetega. Paraku on selliseid 
abiaineid tegelikkuses vähe, ning abiainete ohutus on viimasel ajal lastearstide 
ja eelkõige neonatoloogide jaoks järjest teravamalt tähtsustatud (Hall et al. 
2004). Abiainetega seonduv on võrreldes toimeaineid puudutavate seadustega 
olnud vähem reguleeritud ning lastel nende ohutust reeglina kliiniliselt hinnatud 
ei ole. Siiski on täiskasvanutele ohutud abiained põhjustanud lastele 
manustamisel traagilisi tagajärgi. Näiteks säilitusainena kasutatavat 
bensüülalkoholi on seostatud enneaegsetel vastsündinutel tekkinud 
intravaskulaarse hemorraagia ja surmajuhtumitega (Hiller et al. 1986). 
Hetkeseisuga on abiainete tegelik toksilisus vastsündinutele siiski täpselt 
teadmata. Ka ei olnud seni täpselt teada, kui paljude erinevate abiainetega vast-
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sündinud ravi käigus kokku puutuvad või kui suur osa vastsündinutel kasutatud 
ravimitest sisaldab neile potentsiaalselt toksilisi abiaineid.  
 
Uurimistöö eesmärgid  
Uurimistöö peamisteks eesmärkideks oli kirjeldada ja analüüsida laste farmako-
teraapiat, hinnata OL/UL ravimite kasutuse määra ning seda, millisel määral 
puutuvad vastsündinud haiglaravi jooksul kokku ravimites olevate abinetega 
ning kui suur osa nendest abiainetest võivad olla neile toksilised.  
 Konkreetsed eesmärgid:  
1. Kirjeldada Eesti laste ambulatoorset ravimikasutust ning vastsündinute ravi 
haiglas;  
2. Võrrelda ambulatoorset antibiootikumide määramist Eesti ja Rootsi lastele;  
3. Hinnata lastele määratud ravimite ravimiomaduste kokkuvõtetes olevat infot 
selle kohta, kas ravim on lastel kasutamiseks näidustatud; 
4. Tuvastada laste ja vastsündinute farmakoteraapias need kitsaskohad, kus 
ravimeid kasutatakse kõige rohkem, kuid samas ametlik pediaatriline info 
kõige sagedamini puudub; 
5. Võrrelda lapsi ja vastsündinuid puudutava info olemasolu ravimiomaduste 
kokkuvõttes ja teistes sageli kasutatavates ravimiinfo allikates nagu Briti 
Rahvuslik Formular (ingl.  British National Formulary, BNF) ja Thomson 
Micromedex andmebaasis; 
6. Luua Eesti vastsündinutele haiglaravi jooksul ravimite koostises manustatud 
abiainete põhjal klassifikatsioon lähtuvalt abiainete võimalikust toksilisusest; 
7. Kirjeldada potentsiaalselt toksiliste abiainete esinemist vastsündinutel ka-
sutatud ravimites; 
8. Kirjeldada hospitaliseeritud vastsündinute kokkupuudet neile potentsiaalselt 
toksiliste abiainetega.  
 
Patsiendid ja metoodika  
Käesolev uurimus sisaldab kahte andmebaasidele põhinevat ja ühte pro-
spektiivset vaatlusuuringut ning viimase põhjal tehtud Post-hoc analüüsi. 
Eesti lastele ambulatoorselt määratud retseptiravimite kasutuse ja OL/UL 
ravimikasutuse määra uuring põhineb ajavahemikul 1.01.2007–31.12.2007 kuni 
19a isikutele välja kirjutatud retseptidel Eesti Haigekassa Retseptiravimite 
andmebaasist. 
 Vastsündinute ravimikasutuse ja OL/UL ravimikasutuse määra uurimiseks 
dokumenteerisime prospektiivselt ajavahemikel 01.02–01.08.2008 Tartu Üli-
kooli Kliinikumi ja 01.02–01.08.2009 Tallinna Lastehaigla neonatoloogia 
osakonda hospitaliseeritud kuni 29 päevaste vastsündinute ravimikasutuse.  
 Vastsündinute ravimikasutuse uuringu andmete põhjal hindasime ka vast-
sündinute kokkupuudet neile potentsiaalselt toksiliste abiainetega. Selleks 
tuvastasime ravimiomaduste kokkuvõttest või pakendi infolehelt ravimite 
koostises olevad abiained ning jaotasime nad kirjandusallikate alusel võimaliku 
toksilisuse alusel meie enda loodud klassifikatsiooni järgi rühmadesse.  
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 Eesti ja Rootsi laste antibiootikumikasutust võrdlev uuring põhines aja-
vahemikul 1.01.2007 – 31.12.2007 mõlema riigi lastele ambulatoorselt välja 
kirjutatud retseptide analüüsil, mis pärinesid Eesti Haigekassa Retseptiravimite 
andmebaasist ja Rootsi Retseptiravimite andmebaasist.  
 
 
Peamised tulemused 
Ambulatoorne retseptiravimite kasutus 
Eesti lastele kirjutati välja 2007. aastal 467 334 retsepti 851 ravimpreparaadile 
ja 309 toimeainele. Keskmiselt määrati 1,7 retsepti lapse kohta. Alla kuue aas-
tastele lastele määrati kaks korda rohkem retseptiravimeid (2,5 retsepti lapse 
kohta) kui ülejäänud vanuserühmadele. Kõige sagedamini määrati süsteemseid 
antibakteriaalseid ravimeid, hingamisteedesse toimivaid ning dermatoloogilisi 
ravimeid. Kolmveerand retseptidest (77%) kuulus neisse kolme ravimirühma. 
Kolmandik (31%) retseptidest oli OL, neist enamuse (29%) puhul polnud lapsi 
ravimiomaduste kokkuvõttes mainitud ning 2% retseptidest (106 erinevat 
toimeainet) olid vastunäidustatud. 42% vastunäidustatud ravimitest ei olnud 
lastele sobivad suure kõrvaltoimete riski tõttu. Kõige suurem OL ravimite osa-
kaal oli urogenitaalsüsteemi ravimite hulgas (97%), järgnesid dermatoloogilised 
(74%) ja kardiovaskulaarsüsteemi ravimid (61%).  
Ambulatoorne UL ravimite kasutus oli harv, vaid 0.05% retseptidest  
6 ravimile.  
Kasutatud ravimite kohta erines pediaatriline info erinevates allikates kõige 
suuremal määral kesknärvisüsteemi ravimite ja antibiootikumide osas.  
 
Eesti ja Rootsi laste ambulatoorne antibiootikumikasutus 
Eesti lastele kirjutati 2007. aastal ambulatoorselt välja poole rohkem anti-
biootikumi retsepte kui Rootsi lastele, vastavalt 616 vs. 353 retsepti 1000 lapse 
kohta. Eestis määrati 22 ja Rootsis 50 erinevat antibiootikumi, kuid 90% 
retseptidest olid mõlemas riigis välja kirjutatud kaheksale toimeainele. Kõige 
sagedamini manustatud antibiootikumide grupp oli penitsilliinid (74% kõigist 
retseptidest Rootsis ja 49% Eestis). Eestis määrati sagedamini laia toime-
spektriga penitsilliine nagu amoksitsilliini ja selle kombinatsiooni beta-lakta-
maasi inhibiitoriga, samas Rootsis olid pooled retseptid kitsa toimespektriga 
fenoksümetüülpenitsilliinile. 
 
Vastsündinute ravimikasutus haiglas 
Kõigist 490st uuringuperioodil hospitaliseeritud vastsündinust said ravimeid 
71%. Neile määrati 1981 korral 115 erinevat ravimit. Keskmiselt sai iga vast-
sündinu 4 erinevat ravimit. Kõige sagedamini kasutati antibakteriaalseid, 
kardiovaskulaarsüsteemi ja kesknärvisüsteemi ravimeid. Kõik ravitud vast-
sündinud said vähemalt ühte ravimit, millel puudub müügiluba või ametlik 
näidustus vastsündinutel kasutamiseks. Mitte ühelgi kasutatud meeleelundite, 
skeletilihassüsteemi, seedekulgla ja ainevahetuse, urogenitaalsüsteemi haiguste 
ravimil ja suguhormoonil polnud SPCs infot vastsündinutel kasutamiseks.  
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Vastsündinute ravimiseks vajalik info erines infoallikates oluliselt. Kõige 
suurem erinevus esines ajalisi vastsündinuid puudutavas informatsioonis – 
määratud ravimitest 67%-l oli info olemas BNFCs, 38% Micromedexi andme-
baasis ja vaid 24% Eesti SPCs.  
 
 
Vastsündinute kokkupuude ravimites olevate  
potentsiaalselt toksiliste abiainetega 
Enamus kasutatud ravimitest (87%; 93/107) sisaldas vähemalt ühte abiainet. 
Kokku said vastsündinud ravimitega 123 erinevat abiainet. Kolmandik (42/123) 
abiainetest klassifitseeriti potentsiaalselt ohututeks, teine kolmandik (47/123) 
potentsiaalselt vastsündinutele toksiliseks. Viimati mainitud kategooria sisaldas 
ka kaheksat juba teadaolevalt vastsündinutele toksilist abiainet – parabeene, 
sahhariin naatriumi, naatriumbensoaati, bensüülalkoholi, bensalkooniumklo-
riidi, propüleenglükooli, polüsorbaat 80 ja etanooli.  Ülejäänud 34 abiaine kohta 
ei leidunud kasutatud kirjandusallikates ohutusalast infot või ei olnud abiaine 
kirjeldus ravimiomaduste kokkuvõttes piisav kirjanduseotsingu tegemiseks.  
Ravitud vastsündinutest 97% (339/348) said ravimite koostises vähemalt ühe 
potentsiaalselt toksilise abiaine ja 88% said vähemalt ühe teadaolevalt toksilise 
abiaine. Kasutatud ravimitest 68% sisaldasid vähemalt ühte potentsiaalselt 
toksilist ning 31% teadaolevalt toksilist abiainet. 
 
 
Järeldused  
I Eesti lastele ja vastsündinutele määratakse ambulatoorselt ja ka haiglas 
suurel hulgal OL ravimeid. Et laste farmakoteraapiat ratsionaalsemaks 
muuta, on vaja diagnoosidega lingitud farmakoepidemioloogilisi uuringuid 
sagedamini lastele määratud ravimirühmades.  
II  Eesti ja Rootsi laste ambulatoorne ravimikasutus erineb olulisel määral nii 
kvantitatiivselt kui kvalitatiivselt.  Eesti lastele määratakse antibiootikume 
sagedamini ning kasutatakse ka laiema toimespektriga ravimeid kui Rootsi 
lastele. See viitab Rootsis toimivale riiklikule strateegiale sarnase tegevuse 
vajalikkusele Eestis, et ennetada antibiootikumide väärkasutust. Ravimi-
kasutuse auditid peaksid keskenduma antibiootikumide ratsionaalsele 
kasutusele ning tõenduspõhiste ravijuhiste järgimisele.  
III  OL/UL ravimikasutuse osakaal on Eestis sarnaselt Lääne-Euroopas tehtud 
uuringutega kõrge. Võrreldes süsteemselt manustatud ravimitega, on 
nahale manustatavate ravimid sagedamini OL. OL retseptide osakaal on 
suurem ka alla 2 a lastel võrreldes vanemate lastega. Seetõttu tuleks 
nooremaid lapsi ning nahale manustatavaid ravimeid esile tõsta lastel enim 
uurimist vajavate ravimite nimekirjas.  
IV UL retseptide osakaal oli ambulatoorsetest retseptidest väike. Seevastu 
hospitaliseeritud vastsündinutele määratud ravimitest 25% ja määramis-
kordadest 22% olid UL. See näitab vastsündinute ravimiseks vajalike 
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ravimite kohaliku ja ka Euroopa tsentraalse müügiloa puudumist ning 
vajadust ametliku sekkumise järele. 
V Ravim klassifitseeriti OL ravimiks kõige sagedamini seetõttu, et ravimi-
omaduste kokkuvõttes puudus info kasutamise kohta lapsel või 
vastsündinul. Spetsiifilistest ravimiinfo käsiraamatutes nagu Briti Rah-
vuslik Formular Lastele või andmebaasides nagu Micromedex on oluliselt 
rohkem pediaatrilist infot kui ametlikus ravimiomaduste kokkuvõttes. 
Kuna paljude OL ravimite kohta on olemas piisavalt kliinilist infor-
matsiooni lastel kasutamise kohta, oleks vajalik vaid nende ravimite 
ravimiomaduste kokkuvõtete värskendamine. Kui ravimit ei soovitata lastel 
kasutada, siis tuleb selle põhjus ravimiomaduste kokkuvõttes välja tuua, et 
teavitada ravimi tarvitajaid ja määrajaid võimalikest ravimi kasutamisega 
seotud ohtudest lastel või ebaefektiivsest toimest.  
VI Kolmandik hospitaliseeritud vastsündinutele ravimitega manustatud abi-
ainetest klassifitseeriti vastsündinutele potentsiaalselt ohtlikeks, kuid neist 
vaid kaheksat on varem vastsündinutele ohtlikuks liigitatud. Hetkel on 
vajadus valideeritud klassifikatsiooni järele, mille alusel saaks abiaineid 
ohtlikkuse järgi jaotada.  
VII Praktiliselt kõik ravimeid saanud vastsündinud said uuringuperioodil 
ravimeid, mis sisaldasid vähemalt ühte neile potentsiaalselt ohtlikku abi-
ainet. Kuna avaldatud informatsioon abiainete kohta on vähene, on äärmi-
selt oluline ravimites olevate abiainete põhjalik toksikoloogiline hindamine 
lähtuvalt nende potentsiaalsest toksilisusest vastsündinutele. Abiainetest 
tulenevad potentsiaalsed ohud vastsündinutele ning ka abiainete kvantita-
tiivsed kogused ravimis tuleb teha apteekritele ja vastsündinuid ravivatele 
arstidele kättesaadavaks, et oleks võimalik valida vastsündinule sobivai-
maid ja ohutumaid ravimeid.  
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